Changchun Baike Biotechnology Co., Ltd. 2025 Environmental, Social and Corporate Governance Report
Stock abbreviation: Baike Biotech Securities Code: 688276 Listed on the Science and Technology Innovation Board of Shanghai Stock Exchange
Environmental, Social and Corporate Governance Report
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT IN 2025
Changchun Baike Biotechnology Co., Ltd.
Company address: No. 1260, Huoju Road, High-tech Industrial Development Zone, Changchun City
Contact number: 0431-81871518
Changchun Baike Biotechnology Co., Ltd. Email: [email protected]
2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
About this report Data source and reliability guarantee This report is the third environmental, social and corporate governance report released to the public by Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "Baike Biotechnology" or the "Company"). It adheres to the principle that unless otherwise specified, the information and data cited in this report are derived from the company's internal documents or relevant public information. This report has been confirmed by management and is based on the principles of authenticity and reliability on April 20, 2026. It discloses to all stakeholders the work and results achieved by Baike Biotech in the fields of environment, society and governance in 2025. After being approved by the board of directors, the board of directors and all directors guarantee that the contents of this report do not contain any false records, misleading statements or major omissions.
time range
currency unit
Unless otherwise stated, the organizational scope covered by this report is the Company and its subsidiaries. This report is an annual report, and the reporting period is from January 1, 2025 to December 31, 2025.
Some content exceeds this period.
Unless otherwise specified, the currency unit is RMB.
Compilation basis
This report is obtained based on the Shanghai Stock Exchange's "Shanghai Stock Exchange Self-Regulatory Guidelines No. 14 - Sustainability Report (Trial)" and the Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Report
The disclosure requirements for environmental and social responsibility information of companies listed on the Science and Technology Innovation Board in the "Shanghai Stock Exchange's Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board No. 1 - Standardized Operations",
This report is published in Chinese. You can view and download it on the Shanghai Stock Exchange website (www.sse.com.cn) and the company's official website (www.bchtpharm.com). It was compiled based on some of the reference indicators contained in the "Reference Indicator System for ESG Special Reports of State-owned Enterprise Holdings Listed Companies" of the State-owned Assets Supervision and Administration Commission of the State Council. report parameters
this report.
Consider the information disclosure of the Global Sustainability Standards Board (GSSB) Sustainability Reporting Standards (GRI Standards) and the United Nations Sustainable Development Goals (SDGs).
Lu asked.
Report Preparation Principles Contact Information
Your valuable opinions are crucial to the company's continuous improvement of environmental and social performance. If you have any questions or suggestions about this report, please contact the company through the following methods: Importance
Based on the results of stakeholder communication and using the method of importance assessment, we identified the company's important issues during the reporting period, and then prepared this report around the important issues. Address: No. 138, Zhuoyue Street, Chaoyang District, Changchun City, Jilin Province
Tel: 0431-81871518
Quantify
E-mail: [email protected] Timely attach notes stating the standards, methods and applicable assumptions used for quantitative data.
Consistency
Wherever possible and unless otherwise noted, the statistical methods disclosed are consistent with those reported in previous years to ensure meaningful comparisons.
balance
Objectively and fairly report the company's ESG performance during the reporting period to avoid inappropriately affecting readers' decisions, judgments or choices.
01 02 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Directory
CONTENTS
Chairman's speech 05 Toughness and ingenuity
Light up the glow of health
About Baik Bio 07
ESG management 11 Adhere to innovative research and development 45 Adhere to scientific and technological ethics 49 Stabilize supply security 51 Improve product quality 53
Protect data security 56
01 04
Consolidate the foundation and strengthen the foundation
Anchor green development goals, governance innovation and efficiency
Environmental compliance management 17 Adhere to the leadership of party building 59 Lean resource utilization 19 Consolidate the cornerstone of governance 61 Adhere to pollution prevention and control 21 Strengthen compliance and risk control 64 Share climate responsibility 24 Observe business ethics 67 Smooth communication channels 69
Building Harmony Appendix
Let’s work together for a better future. Indicator index 73 Protect employees’ rights and interests 29 Key performance table 76 Implement safe production 37 Feedback 83 Spread hope for charity 40 Disclaimer 84
03 04 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Chairman's speech
Innovation as the core, empowering high-quality development of health undertakings
In 2025, Baike Biotechnology will move forward steadily on the biotechnology track, and will continue to work hard on the journey of environment, society and governance (ESG). As a biological enterprise that protects human health,
As an industry, we always firmly believe that the long-term value of an enterprise lies not only in technological breakthroughs and performance growth, but also in its respect for the environment, its responsibility to society, and its persistence in governance. Here,
As a biotechnology company, technological innovation is the core carrier for us to fulfill our social responsibilities. In 2025, we will adhere to our original aspiration of "innovation for the people" and continue to make progress in the fields of vaccines and antibody research and development. On behalf of the company's board of directors, I would like to express my most sincere gratitude to all colleagues and partners who have long cared about and supported the development of Beike Biotech!
To tackle tough problems, focus on the needs for the prevention and control of major diseases, promote clinical research and results transformation of multiple products, and protect public health with high-quality biological products. We strictly adhere to bioethics and safety standards to ensure that every technological breakthrough can withstand the test of ethics and time. At the same time, we actively share technological achievements, assist in the formulation of industry standards, and use innovation to promote the overall development level of the industry.
Governance as the basis to build a solid foundation for sustainable development
We have always regarded a sound governance system as the core support for ESG practices, built a three-tier governance structure that penetrates the board of directors, management and grass-roots operations, and established strategic and sustainable
Responsibility in mind, building a win-win ecological pattern for all parties
Continuous Development Committee ensures the scientific nature of strategy formulation and the closed-loop implementation. In 2025, we will further optimize the ESG-related management system and realize the organization and systematization of ESG management.
Degree and normalization. By strengthening compliance management and risk prevention and control, and building a full-chain biosafety traceability system, we use high-standard governance to protect the high-quality development of the company.
The growth of an enterprise cannot be separated from the nourishment of society, and giving back to society is the original intention of Baike Biotech. In 2025, we will continue to improve the employee care system and build a comprehensive vocational training and growth platform to protect employees' occupational health and legitimate rights and interests, so that the results of corporate development will benefit every employee. We deepen "penetrating" supply chain ESG management and build a green ecological chain with our partners. In addition, we actively participate in public welfare undertakings, continue to make efforts in public health science popularization and other fields, and convey the company's warmth with practical actions.
Looking to the future, there is still a long way to go but there is much to be done. ESG is not an "additional question", but a "compulsory course" for the high-quality development of enterprises. It is also the core green approach for Baike Biotech to build long-term competitiveness and practice the concept of ecologically friendly development.
heart element. In the future, we will continue to deepen the deep integration of ESG and corporate strategy, continue to improve governance, continue to make breakthroughs in green transformation, and continue to create innovation and empowerment. The original intention of biotechnology is to protect life, and the prerequisite for protecting life is to protect our common home. In 2025, we will take every action to implement the development logic of "carbon reduction means cost reduction, recycling means strength, and continue to assume social responsibilities. We have the same original intention and will not slack off in our actions. Baike Biotechnology will always adhere to the mission of "committed to biotechnology and create a healthy future" and join hands with all shareholders to jointly increase efficiency. We will contribute Baike's solutions to the green transformation of the industry. We work with partners and all walks of life to take ESG as our wings, ride the wind, and write a more exciting chapter on the road of biotechnology and sustainable development!
05 06Product situation
With the promotion of the "Healthy China" strategy, my country's vaccine market has gradually formed a "category of vaccine protection".
The two-wheel drive pattern is to promote the upgrading of basic and second-category vaccines. Immunization program vaccines as public
The cornerstone of public sanitation is to achieve high coverage through government procurement. However, it is limited by neonatal
Due to the impact of declining numbers and saturated vaccination rates, the growth space has tended to be stable. non-immunization program
Miao has become the core engine of market growth, and its market share continues to increase. face people
Faced with multiple challenges such as changes in population structure, pressure on traditional vaccine prices and intensifying market competition,
China's vaccine industry is undergoing a profound transformation. The core driving force for industry development has been based on regulations
Model expansion gradually shifts to a high-quality development stage led by technological innovation and product upgrades Company Profile
segment. The company currently has live attenuated chickenpox vaccine and freeze-dried nasal spray live attenuated influenza vaccine.
Changchun Baike Biotechnology Co., Ltd. (stock code: 688276) was established in 2004. It is an innovative biopharmaceutical enterprise focusing on the prevention and treatment of infectious diseases. It mainly produces vaccines, live attenuated herpes zoster vaccine, and live attenuated nasal spray influenza vaccine (liquid preparation).
It is engaged in the research and development, production and sales of human vaccine products. In June 2021, the company was successfully listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. and other approved vaccine products, while also deploying 13 vaccines under development and 3 types of infectious disease prevention
Related monoclonal antibodies have formed a product pipeline with clear hierarchy and continuous innovation.
With years of technology accumulation, the company has built five cores through independent research and development.
Technology platforms, namely “Virus Large-Scale Culture Technology Platform” and “Preparation and Adjuvant Technology Platform”
As the company's core product, the live attenuated varicella vaccine has undergone multiple technological upgrades since its launch in 2008. It is the first varicella vaccine in China that removes animal-derived gelatin, significantly reducing the cost of Taiwan's "genetic engineering technology platform", "bacterial vaccine technology platform" and "mRNA vaccine".
the incidence of adverse reactions. With its 36-month validity period, this product has become the most stable similar product in the world. It has maintained a leading position in market share for a long time, and its cumulative batch release volume has reached the technical platform." Relying on the advantages of these five major platforms, the company firmly implements innovation-driven development
The disease treatment base has provided nearly 100 million doses, making an important contribution to the prevention and control of the chickenpox epidemic in my country. The freeze-dried nasal spray live attenuated influenza vaccine is a project development strategy of the global influenza vaccine action plan of the company in cooperation with the World Health Organization. Closely focusing on national strategic needs and market orientation, it has formed a vaccine, poison, cause, and bacteria coverage.
For this purpose, as the only influenza vaccine administered through nasal spray in China, it has greatly improved the convenience and compliance of vaccination. Nasal spray influenza live attenuated vaccine (liquid preparation) is based on the original nasal spray influenza epidemic regulations and industrial properties.
A complete technical system from research and development to industrialization. At present, the company’s product pipeline layout is under development. Model Zuo Cheng Yin
The improvement of the dosage form based on the freeze-dried dosage form of seedlings has further improved the convenience and compliance of product use. The live attenuated herpes zoster vaccine approved for marketing in 2023 has successfully broken the evolutionary agent technology vaccine
Extensive, covering varicella-zoster vaccine, rabies vaccine, influenza vaccine, and monoclonal monoclonal technology product monopoly. This product has been verified by phase III clinical trials with a scale of 10,000 people, covering all age groups aged 40 and above, filling the domestic market gap in this field. Nourishing Techniques and Leveling Techniques
In the fields of long-lasting antibody drugs, combination vaccines and innovative vaccines, the product portfolio is growing day by day.
technology platform
surgery platform
More abundant. At the same time, the company has more advanced equipment such as cell factories and bioreactors.
flat
Taiwan
Production technology, with efficient and stable large-scale animal cell culture capabilities. Pass
With mature production technology and perfect quality management system, the company continues to ensure product quality
Quantity safety and stability.
4546
In terms of R&D innovation, the company has established five major technology platforms: virus large-scale culture, preparations and adjuvants, genetic engineering, bacterial vaccines and mRNA vaccines, providing strong support for continued product innovation. As of the end of the reporting period, the live attenuated nasal spray influenza vaccine (liquid preparation) has been launched and is undergoing phase III clinical trials for people aged 18-59 years old. The adsorbed acellular diphtheria pertussis (three-component) combination vaccine is undergoing phase III clinical trials. Rabies monoclonal antibody has completed phase II clinical work, and tetanus monoclonal antibody is undergoing clinical trials. Phase Ib and II clinical trials are underway, phase I clinical trials of freeze-dried rabies vaccine (human diploid cells) are ongoing and phase III clinical trials are being prepared, herpes simplex virus type II mRNA vaccine (HSV-2 vaccine) is undergoing phase I clinical trials, and clinical trial applications for 6 products including adjuvant influenza vaccine have been approved. In addition, the company has proactively planned innovative projects such as RSV vaccines and antibodies, and Alzheimer's disease therapeutic vaccines, and continues to enrich its product pipeline. In the future, Baike Biotech will continue to deepen its efforts in vaccine research and development and innovation, serve public health with more high-quality products, and contribute to the construction of "Healthy China".
07 08mRNA
2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
walk into
100g Bio
Category I vaccines are two-wheel drive. Category II vaccines maintain the basic pattern and promote upgrading.
Lyophilized Nasal Spray Herpes Zoster Nasal Spray Influenza Attenuated Chickenpox Influenza Attenuated Attenuated Live Vaccine Live Vaccine Live Vaccine Live Vaccine
Approved vaccine products
Five core technology platforms
epidemic
seedlings
technology
technique
flat
Taiwan
live attenuated varicella vaccine
2008 36
Best Global Stability Leadership Years Months
Listed, valid period, similar products, long-term market share. The company has established a complete marketing system, and its products cover 31 provinces, autonomous regions, and municipalities across the country except Hong Kong, Macao, and Taiwan. With in-depth terminal marketing network and professional market
With its service team, the company can quickly respond to market demand, ensure timely and efficient product supply, provide customers with quality services, and establish a good brand image in the industry.
2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
corporate culture
"Committed to biotechnology and creating a healthy future" is the corporate mission of Baike Biotech, a 2025 listed company.
performance briefing
fate. Since its establishment, the company has always been adhering to the principles of "standardization, innovation, focus, tolerance, dedication to biotechnology, and creating a healthy future. Excellent Practice Listed Company Evaluation of the Performance of the Board Secretary's Duties
The development concept of "4A Sharing" is based on "being a first-class enterprise, manufacturing first-class products, and cultivating first-class talents"
In order to achieve development goals, we will continue to deepen our efforts in the field of infectious disease prevention and control.
China Public Companies Association China Public Companies Association
Baike Bio Under the guidance of the innovative development concept, the company has established a complete R&D innovation system, focusing on the research, development, production and sales of human vaccines and biological drugs. In the future, the company will continue to
Optimize the strategic layout of products, focus on promoting the research and development of adult vaccines, multi-linked multivalent vaccines, antibody drugs and mRNA vaccines and other cutting-edge fields, and continuously strengthen the core value through technological innovation.
maintain competitiveness and contribute Chinese wisdom and Chinese solutions to global public health. On the road to pursuing excellence, Baike Biotechnology will continue to maintain strategic focus and be open and inclusive.
We welcome industry changes with a positive attitude and work with partners from all walks of life to create a healthy future.
Best 2025 Investor Relations Management Science and Technology Innovation Power·
Listed company's annual scientific and technological innovation product social recognition
Securities Market Weekly Southern Weekend Newspaper
Honorary Awards: 100g Gram Biotech Ganwei® Herpes Zoster Live Attenuated Vaccine
ESG Ratings
The third session in 2024
Listed Company Golden Bull Award Guoxin Cup ESG Technology Leadership
"Golden Letter Award" Golden Bull Award
China Securities News China Securities News
Huazheng ESG Rating SynTao Green Finance ESG Rating AA Grade A-Grade Baike Bio Biotech
listed company
Jilin Province
Board of Directors Office
Honest enterprise
Good Practice
Jilin Provincial Credit Rating Center China Association of Public Companies
100g Bio 100g Bio
09 10 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
ESG
ESG strategy
Management Baike Biotechnology always adheres to the development philosophy of "standardization, innovation, focus, tolerance and sharing"
concept, adhering to the corporate belief of "committed to biotechnology and creating a healthy future", closely integrating corporate standardization, innovation, focus, inclusiveness, and shared development strategies with the practice of operational sustainability, and attaching great importance to ESG in the enterprise
Guiding and driving role in governance and production operations.
Development concept
governance
dual importance analysis
With the mission of "committed to biotechnology and creating a healthy future", Baike Biotech deeply integrates the concept of sustainable development into corporate strategy and daily operations, continues to optimize the ESG governance system, and promotes
promote the coordinated development of economy, environment and social value. The Strategy and Sustainable Development Committee under the company's board of directors systematically coordinates ESG strategic planning and execution to ensure sustainable development.
The development goals are closely integrated with the company's long-term operations; the committee is convened by the chairman and consists of three directors, including independent directors, to ensure the professionalism and independence of decision-making. In the first step, the company initially identified 20 issues related to company development, environment, society and other aspects based on the topic setting of the Shanghai Stock Exchange's "Guidelines", industry characteristics, company nature, industry development stage, and key issues in identifying its own business model. The company has built an ESG governance structure with clear layers and clear rights and responsibilities to improve the company's ESG governance effectiveness. The board of directors is responsible for overall decision-making and deployment; strategy and sustainable development
Under the authority of the Board of Directors, the Committee assumes ESG strategic planning and supervision responsibilities:
Step 2: For the identified issues, the company understands and collects opinions from stakeholder importance analysts through questionnaire surveys, expert assessments, industry benchmarking, etc., conducts impact importance and financial importance assessments, and determines the impact importance and financial importance scores of each issue. Strategy and Sustainability Committee
Research and propose the company's sustainability Study and propose the company's ESG Follow-up and check the implementation of ESG work Review the company's sustainable development,
Materiality Category Explanation Continue to develop investigation methods and ESG-related matters Development strategies and stakeholder implementation and improvement to ensure anti-corruption and ESG-related matters reporting, and
item suggestions. Integrity, occupational safety and health, the substantive areas of focus, are reported to the Board of Directors.
Impact Importance Whether the company's performance on the corresponding issues will have an impact on the economic, social and environmental issues suggested in the questionnaire. Community relations and other important sustainable
significant impact on the environment
Management and decision-making of development issues
The mechanism complies with relevant laws and regulations
Financial materiality Questionnaire requirements on whether the topic anticipates the company's business model in the short, medium and long term.
model, business operations, development strategies, financial conditions, operating results,
Cash flow, financing methods and costs will have a significant impact
In order to ensure the effective implementation and comprehensive implementation of ESG work, the company has established a cross-departmental collaborative execution mechanism under the Strategy and Sustainable Development Committee. Various departments dispatched different consultants
Relevant personnel under the topic participate in ESG work and are responsible for coordinating and executing ESG-related decisions of the responsible departments.
Based on the topic setting of the Shanghai Stock Exchange's "Guidelines", industry characteristics, company nature, industry development stage, and the future of its own business model, the company will continue to optimize the ESG governance model, promote the in-depth integration of ESG concepts into all aspects of corporate operations, and further improve the company's ESG performance. In conjunction with various stakeholders, the company has initially identified 20 issues related to company development, environment, society, etc. Step 3
Together we realize the dual values of sustainable management and social responsibility. Comprehensive analysis of important issues
Issues of financial importance identified by the company include supply chain management and innovation drive, and issues of dual importance include response
Climate change and production safety.
11 12 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Stakeholders Needs and Expectations Communication Channels
Issues of impact importance Issues of dual importance
Government departments · Operate in compliance with laws and regulations · Promote local economic development · Regular exchange of official documents · Organize policies to learn data security and customer privacy protection
and regulatory agencies
Energy utilization · Pay taxes in accordance with the law · Fight corruption and promote integrity · Accept supervision and inspection
social contribution
Water resources utilization · Respond to national policies · Participate in briefing sessions held by government units
Stakeholder communication
Tackling climate change
Pollutant emissions
Anti-commercial bribery and anti-corruption
safe production
waste disposal
Science and technology ethics
Shareholders and investors · Economic performance · Protection of shareholders’ rights and interests · Shareholders’ meetings · Accepting institutional research on circular economy
Product and service safety and quality
· Information disclosure and transparency · Compliance and risk management · Regular information disclosure · Roadshows and online communication with investors
Impact Environmental Compliance Management
ring
heavy
want
Sexual non-material issues Financially material issues Customers · Product quality and safety · Customer service · Customer satisfaction survey · Regular visits
· R&D innovation · Information security and privacy protection · Daily email and phone communication · After-sales service and complaint due diligence
Ecosystem and Biodiversity Conservation
supply chain management
rural revitalization
Innovation-driven suppliers · Honest cooperation · Win-win development · Irregular communication · Supplier training treats small and medium-sized enterprises equally
· Good and stable cooperative relationship · Supplier review and evaluation · Supplier questionnaire to combat unfair competition
Partners · Promote industry development · Intellectual property protection · Regular communication mechanism · Financial importance of academic exchange conferences
· Good and stable cooperative relationship · Cooperation agreement · Carry out industry-university-research cooperation
Stakeholder communication
Employees · Occupational health and safety · Career development opportunities · Regular employee training · Employee questionnaire
· Salary and benefits · Protection of rights and interests · Organizing employee activities · Regular internal meetings and online communication Baike Biotech adheres to the principles of equality, interaction, transparency and integrity, and establishes multiple communication channels with stakeholders. Through irregular online and offline meetings, questionnaires, and
We use social media platform communication and other methods to promptly understand and respond to the expectations and demands of stakeholders.
Community and the public · Protect resources and environment · Rural revitalization · Carry out volunteer activities · Participate in public welfare activities
· Poverty alleviation and education development · Promote local economic development · Community communication activities
· Charity
13 14 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
solid foundation
Anchoring green development goals
Environmental Compliance Management 17 Lean Resource Utilization 19 Adhere to Pollution Prevention and Control 21 Shared Climate Responsibility 24
SDGs response:
15 16 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
environment
Compliance management ensures the normal operation of environmental protection facilities in the workshop, reduces or reduces the emission of pollutants such as "water, gas, sound, slag", and prohibits unorganized emissions from other departments; departments and workshops should designate dedicated personnel to be responsible for hazardous waste management, identify, classify, collect hazardous waste, and transfer it to the workshop to the hazardous waste storage room, and fill in the "hazardous waste transfer record sheet"; workshops and departments and the EHS department jointly handle relevant environmental issues
Insurance procedures.
Baike Biotech has always adhered to green operations and compliant development, and strictly abides by national laws such as the Environmental Protection Law of the People's Republic of China and the Environmental Impact Assessment Law of the People's Republic of China. In order to continuously improve the efficiency of environmental protection governance and practice the concept of green and low-carbon development, the company focuses on energy saving, consumption reduction, emission reduction and efficiency improvement in the production process, focuses on promoting a number of environmental protection technology transformation projects, implements laws and industry standards, and integrates environmental compliance management throughout the entire production and operation process of the enterprise. The company's EHS department takes the lead in drafting and improving the internal "Environmental Protection Management System" to achieve two-way improvement in environmental protection benefits and production benefits.
Establish an environmental management system of "top-level design, layer-by-layer implementation, and full-process control" to realize environmental management with rules and regulations to follow, and promote the standardization and standardization of environmental compliance management.
Low nitrogen emission reduction transformation
In terms of the construction of the governance responsibility system, the company has established a responsibility matrix in which "all employees are responsible and implemented at all levels" to clarify that environmental management responsibilities are assigned to each person and implemented. Among them, the general manager of the company is a company
The person in charge of the company's environmental protection work is the primary person in charge of environmental protection management. A complete responsibility system provides a solid guarantee for environmental compliance management.
Completed the low-nitrogen renovation of 1 boiler in the Torch Factory and 7 boilers in the Excellence Factory. During the reporting period, the company achieved the "double zero" goal of no environmental safety accidents and no environmental administrative penalties throughout the year. All types of pollutant emissions strictly complied with national and local standards, and hazardous
Cooperation will further improve energy utilization efficiency and help improve regional air quality. Taiwan will standardize the entire process of disposal and closed-loop management of waste, and effectively build a solid defense line for environmental protection compliance.
Fulfill low-carbon environmental protection responsibilities. Low-nitrogen transformation of boilers in Torch Factory Area Low-nitrogen transformation of boilers in Zhuoyue Factory Area
Responsible for supervising the operation of environmental protection work of various departments and systems of the company; responsible for the application and management of the company’s pollution discharge license
Responsible for establishing the company's hazardous waste storage and storage registration ledger; Hazardous waste storage rooms are equipped with dedicated personnel to manage hazardous waste every day
Inspect waste warehouses to eliminate environmental hazards, ensure normal use of hazardous waste rooms, and strictly prevent environmental issues such as leakage, penetration, and spillage. Energy-saving recycling renovation
EHS Department
accident occurs; responsible for the company's declaration, transfer and disposal of hazardous waste and solid waste, and forming a ledger; responsible for the company's
Standardization and compliance of solid waste and hazardous waste storage rooms; responsible for the normal operation of the company's wastewater treatment system
Promote the thermal energy recovery transformation of the exhaust gas outside the No. 6 building of the Excellence Factory, effectively recover the waste heat resources in the exhaust gas, and realize energy recycling; simultaneously complete the recovery and transfer of condensate water in the boiler room to ensure that wastewater discharge meets the standards.
Transform, improve water resource utilization and reduce water waste.
Responsible for the maintenance of environmental protection facilities and equipment, the supervision, management and data statistics of energy (water, electricity, gas); responsible for the boiler
Equipment
Work management of boiler operation to ensure that the boiler complies with safety regulations during operation, saves energy and protects the environment; is responsible for the water production room
Power Department The company has passed environmental management system certification. ISO14001
Work management of water production operation to ensure correct discharge of clean water.
Strictly implement the "three simultaneous" system requirements for environmental protection in construction projects, be responsible for the construction of environmental assessment facilities and equipment for construction projects, and achieve
Engineering Department
Acceptance requirements.
17 18 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
With the support of the normalized monitoring mechanism, the company conducts dynamic tracking and data review of each energy consumption link, and timely discovers operational deviations and energy-saving potential through energy efficiency benchmarking analysis. In response to abnormal energy consumption in the production process, the engineering and technical team took precise measures and formed a three-dimensional lean resource plan that combines equipment modification, process optimization, and intelligent control to continuously improve energy utilization efficiency.
take advantage of
In 2025, the company continued to promote energy structure optimization and energy conservation and consumption reduction. The total energy consumption for the year was 25,722 tons of standard coal, of which clean energy consumption reached 18,072 tons of standard coal, accounting for 70.26% of the total. Green and low-carbon development has achieved remarkable results, achieving coordinated advancement of energy utilization and environmental protection development.
25,722 18,072 70.26
Ton Of which Ton % Based on the core business of vaccine R&D and production, Baik Biotech has achieved coordinated development of efficient energy utilization and energy conservation and consumption reduction by improving the institutional system, strengthening fine management and control, and promoting technological innovation.
Total annual energy consumption/standard coal Clean energy consumption/standard coal The proportion of clean energy consumption is displayed to help enterprises operate sustainably.
energy management
water resources management
In order to standardize the energy management process and improve energy utilization efficiency, the company strictly abides by the Energy Conservation Law of the People's Republic of China, the Circular Economy Promotion Law of the People's Republic of China and other national regulations.
According to the laws and regulations of the country, combined with the actual production and operation of the enterprise, the system construction has been improved internally, and the "Environmental Protection Management System" and "Energy Management System" have been formulated successively, establishing a dual system of "national regulations guide Baik Bio strictly abides by the "Water Law of the People's Republic of China" and other relevant national laws and regulations, and integrates the rational use of water resources and efficient management and control throughout the entire process of the enterprise's production and operation, combined with self-leadership and internal system support" to clarify the responsibilities, processes and standards of energy management, laying a solid foundation for refined energy management. Based on the characteristics of production and operation, we scientifically plan the water distribution, optimize the water structure, effectively improve the utilization rate of water resources through diversified recycling measures, and fulfill the responsibility of water conservation and emission reduction.
The company's energy utilization is mainly concentrated in the key links of vaccine research and development and production. Energy consumption. The company's water resources mainly come from municipal water. In order to minimize the waste of water resources and realize the recycling of water resources, a series of water-saving management and control measures have been targeted: the main types are the purchase of water resources, electricity and natural gas, and also cover official vehicles.
energy
Auxiliary energy types such as oil and cold chain transportation diesel, energy demand and vaccine R&D and production Water resources Electricity Natural gas 1 2 3 4
Consumption type
Suitable for professionalism and standardization.
Introduce rainwater and concentrated water recovery systems. Purchase condensate water recovery devices and standardize cooling water and chilled water pipes. Strengthen water-saving management and control in new projects. The recovered rainwater and concentrated water will be directly discharged to the production process. During the construction of the new project, the existing cooling water in the factory area and the same water will be rationally used for green plant irrigation in the factory area to condense the high-temperature waste heat. The chilled water tank totals 601 tons. The condensed water recovery model will be introduced step by step.
In irrigation and production auxiliary links, all water is recycled and reused, and it can operate stably throughout the year. Through the water-saving machines, we optimize the energy use efficiency from the source and eliminate energy waste. The company has built a three-level energy supervision network, implements a full-process and refined energy management model, and specifically implements a number of controls. It can save about 16,000 water resources per year. Through the recycling model, it has greatly improved the water use process and established water-saving measures: 2,100 tons; tons, which not only achieves water conservation but also achieves high water resource reuse rate, which is the basis. Agreement, and also achieved waste heat efficiency and reduced fresh water consumption;
one two three four use;
Develop a system covering R&D, production, and establish equipment energy efficiency monitoring platforms. Prepare energy-saving operators for positions. Regularly carry out energy usage emissions assessments.
We have a full-process energy-saving system including auxiliary equipment, inventory of core energy-consuming equipment, standardized employee operations, and comprehensive inspection of energy-consuming links.
In 2025, the company's total annual water consumption will be 760,417 tons, of which 741,716 tons of fresh water will be used, and the total reused water consumption will reach 18,701 tons, with reused water consumption accounting for 2.5%. If not, the responsibility will be assigned to the person to ensure that the energy saving status and energy consumption data are carried out, and guide all employees to participate in energy saving. Existing problems will be optimized in a timely manner.
In the future, the company will continue to deepen water resources management, continuously optimize water-saving measures, upgrade water-saving equipment, further improve the level of water resource recycling, and help implement green, low-carbon, and sustainable energy requirements; monitor in real time to accurately grasp consumption and reduce consumption; adjust energy use plans to ensure that each
continue to develop.
Energy dynamics; link energy consumption is always at
Controllable range to achieve energy resources 760,417 741,716 18,701 2.5 of which
Source scientific configuration. Ton Ton Ton %
The company’s total annual water consumption, fresh water consumption, total reused water consumption, and proportion of reused water consumption
19 20 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
persist
In 2025, the company's wastewater discharge data from each plant area is clear and controllable. Among them, the annual wastewater discharge of the Zhuoyue plant is 603,752 tons, the ammonia nitrogen emissions are 0.088149 tons, and the chemical oxygen demand emissions are 14.283805 tons; the annual wastewater emissions of the Torch plant are 5,068 tons, the ammonia nitrogen emissions are 0.0014328 tons, and the chemical oxygen demand emissions are 0.174561 tons. pollution prevention
Excellent factory area
603,752 0.088149 14.283805
tons tons tons
Annual wastewater emissions Annual ammonia nitrogen emissions Annual chemical oxygen demand emissions
In terms of pollutant monitoring and control, the company strictly follows the requirements of the "Measures for the Management of Pollution Discharge Permits" and the "Technical Specifications for Application and Issuance of Pollution Discharge Permits" and scientifically compiles the internal "Self-monitoring"
"Testing Plan" to build a dual monitoring system of "self-monitoring + third-party verification". On the one hand, we carry out regular self-monitoring in strict accordance with the plan to accurately control pollutant discharge activities.
status; on the other hand, a qualified third-party agency is entrusted to conduct comprehensive monitoring of wastewater, exhaust gas, noise and other pollutants every month, and simultaneously issue authoritative monitoring reports to ensure monitoring
The data is authentic, accurate and traceable, preventing emission compliance risks from the source. Torch factory area
5,068 0.0014328 0.174561
Ton Ton Ton Wastewater Management Annual Wastewater Discharge Annual Ammonia Nitrogen Discharge Annual Chemical Oxygen Demand Discharge
Baike Biotech attaches great importance to wastewater management and strictly abides by the "Water Pollutant Emission Standards for Bioengineering Pharmaceutical Industry" (GB21907-2008) and "Boiler Air Pollutant Emissions"
Standards", "Pharmaceutical Industry Air Pollutant Emission Standards" (GB37823-2019) and other relevant national standards and specifications, combined with the actual production and operation of enterprises, to effectively prevent wastewater discharge risks
risk and protect the ecological environment.
Exhaust gas management
Baike Biotechnology has always regarded waste gas compliance management as an important part of environmental protection work. It strictly adheres to the "Boiler Air Pollutant Emission Standards" and "Pharmaceutical Industry Air Pollutant Emission Standards". The wastewater generated during the company's operations is mainly divided into production wastewater and domestic wastewater. For
(GB37823-2019) and other relevant national standards and specifications, build a standardized and normalized exhaust gas management system, make every effort to prevent air pollution risks, and practice green environmental protection responsibilities. The characteristics of the two types of wastewater are concentrated through dedicated sewage treatment stations in the factory.
After the treatment is completed, the discharge will be carried out in strict accordance with the relevant requirements of the pollution discharge permit to ensure that
In order to ensure that waste gas emissions meet standards, the company continues to strengthen the operation and maintenance management of waste gas treatment facilities, ensuring the stable and efficient operation of various waste gas treatment facilities throughout the year, and the entire process of wastewater discharge during production and operation is controllable and traceable. In order to standardize the entire process operation of sewage treatment,
The generated waste gas will be comprehensively collected and scientifically treated to reduce air pollutant emissions from the source. During the reporting period, the compliance rate for various emission indicators of air pollutants reached 100%, and all wastewater companies have formulated the "Sewage Station Management System" and "Sewage Station Online System Management System"
Air emissions strictly comply with relevant national standards and effectively protect regional air quality.
A series of internal management systems such as the "Sewage Station Handover System" clarify the responsibilities of each position.
Responsibilities, operating procedures and management and control standards to standardize and standardize the operation of sewage treatment stations
Provide solid institutional support.
waste management
In terms of wastewater monitoring and control, the company has built a comprehensive and intelligent monitoring system, focusing on monitoring key indicators such as COD (chemical oxygen demand), ammonia nitrogen, and PH. After testing,
Baike Biotech attaches great importance to waste management, focusing on strengthening the compliance control of the entire process of hazardous waste, strictly following the "National Hazardous Waste Directory" and "all monitoring indicators of the Hazardous Waste Transfer Management Office comply with the limit requirements of the "Bioengineering Pharmaceutical Industry Water Pollutant Discharge Standard" (GB21907-2008). Among them, the sewage station built by the company is monitored online
A series of systems such as the Law, "Technical Guidelines for the Development of Hazardous Waste Management Plans and Management Accounts" (HJ1259-2022), and "General Principles of Hazardous Waste Identification Standards" (GB5085.7-2019) can realize full-process intelligent operations such as wastewater flow monitoring, automatic collection of wastewater samples, water sample analysis and analysis data statistics, and uploading, greatly improving the accuracy of wastewater monitoring.
In accordance with national regulations and standards, we strictly implement the relevant requirements of the "Standard Operating Procedures for the Destruction of Hazardous Wastes" to ensure that the entire process of disposal of hazardous waste generated during production operations is legal, accurate and efficient, and to achieve intelligent upgrades in wastewater management. During the operation of the company's sewage treatment station, the compliance rate of various water pollutant discharge indicators reached 100%.
It is safe and harmless, and effectively fulfills the main responsibility of environmental protection.
21 22 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
In the daily management and control of hazardous waste, the company strictly implements the requirements for the entire process of classification, packaging, temporary storage, and recording to prevent various environmental risks. In terms of classification and packaging, hazardous wastes are shared
Carry out standardized and classified packaging according to specific categories to ensure that the packaging is tight and intact. Hazardous waste labels are standardized and pasted on the outer packaging. It is strictly prohibited to avoid violations such as "escape, leakage, dripping, and leakage".
In terms of ledger management, each department keeps detailed records of the entire process of hazardous waste generation and temporary storage, and accurately fills in relevant ledgers to ensure that hazardous waste accounts are consistent and traceable; Climate Responsibility
In terms of transfer and disposal, when the hazardous waste storage reaches the specified period and quantity, a third-party hazardous waste treatment company with corresponding qualifications will be responsible for the transfer. After the transfer is completed, the company
Work with a third-party processing company to jointly issue a transfer form, which will be signed and sealed by both parties and submitted to the Environmental Protection Bureau for filing as required to ensure that the transfer process is compliant and verifiable.
Daily management and control of hazardous waste
governance
The company strictly abides by national laws and regulations such as the Environmental Protection Law of the People's Republic of China and the Environmental Impact Assessment Law of the People's Republic of China, and improves classification, packaging, and temporary records based on the company's actual operations.
The internal management system, through the "Environmental Protection Management System" and "Self-monitoring Plan" led by the EHS department, clarifies the specific requirements, management and control processes and monitoring standards for responding to climate change and controlling greenhouse gas emissions, integrating climate risk management into daily environmental protection management, and achieving standardized and normalized management and control.
In terms of the construction of the climate risk management governance system, the company has established a responsibility system that is “consolidated at all levels and all employees are responsible” to clarify the environmental management responsibilities of personnel at all levels and provide a solid organizational guarantee for responding to climate change. Among them, the general manager of the company, as the first person responsible for environmental protection management, coordinates the overall response to climate change and environmental protection work; in order to achieve the standardization and harmlessness of hazardous waste destruction, the person in charge of environmental protection work has clarified a clear division of responsibilities and operating procedures, and established special standard operating procedures for hazardous waste destruction. Among them, danger
As the main person responsible, he takes the lead in promoting the implementation of various related work and achieving results; the leaders in charge of each system (vice president and director) serve as the first person responsible for environmental protection management in their respective fields. The unified waste generation department is responsible for the classified collection, transfer, storage and related record filling of hazardous waste to ensure that source control is in place; the EHS department is responsible for coordinating the ledger of hazardous waste
The team is in charge of system climate risk management and control; managers of relevant departments (including workshop directors), as the first person responsible for environmental protection management in the department, are directly responsible for the summary of front-line climate risk management measures, formulation of annual management plans, approval and filing of relevant procedures, and supervision of the implementation of the entire management and control process. The entire operation process strictly follows the "annual plan and declaration, classified collection
Implementation.
"Collection, transfer, record filling, hazardous waste transfer and filing" standards are promoted to form a closed-loop management system.
In 2025, the company's hazardous waste compliance disposal rate will reach 100%, achieving zero illegal disposal of hazardous waste. Among them, the annual hazardous waste disposal volume of the Excellence Factory was 260.46557 tons; Compacting layer by layer, all employees are responsible for building a climate risk management and governance system
The annual hazardous waste disposal volume in the Torch Factory was 7.400895 tons.
The first person responsible for coordinating the overall response to climate change and environmental management. General Manager of the Company
and environmental protection work
2025
Leading the promotion of various related work 100 Main person responsible Person in charge of environmental protection work
Effective after implementation
%
Compliance disposal rate of hazardous waste of the company
Environmental management in their respective fields. Leaders in charge of each system.
Coordinate and manage systematic climate risk management and control
First Responsible Person (Vice President and Director)
Among them
The department’s first responsibility for environmental management is the managers of each relevant department, who are directly responsible for front-line climate risk management.
Appointment of personnel (including workshop director) Implementation of measures
Excellence Factory Torch Factory
260.46557 7.400895
tons tons strategy
Annual hazardous waste disposal volume Annual hazardous waste disposal volume
Baike Biotech is deeply aware of the ecological challenges brought about by climate change, and has always actively fulfilled its environmental protection responsibilities, integrated climate change response into the entire production and operation process of the company, fully considered ecological and environmental protection factors in the process of carrying out business activities, focused on controlling greenhouse gas emissions, and fully promoted the coordinated development of economic interests and ecological and environmental benefits to achieve a win-win situation and contribute to global climate governance.
23 24 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Affected climate related
Types of risks and opportunities related to climate change Impact on the company Time frame Scope of the value chain of key response initiatives Financial impact
Reasonably configure refrigeration equipment, and give priority to energy-saving and environmentally friendly equipment types; the demand for refrigeration equipment increases, increasing operating costs; temperature-sensitive chemical reagents, warehouses increase operating costs and employee maintenance
Extreme High Temperature Short Term Self-Operation
Strengthen safety management, strictly control the conditions of warehousing links, and conduct regular inspections to prevent explosions, fires and other safety risks in storage links; reduce maintenance costs and reduce financial income
Fire inspections and fire drills are conducted to popularize employees’ fire awareness. acute risk
Physical risks Pay attention to extreme weather warnings, formulate scientific and effective disaster emergency plans, and laboratory precision instruments are extremely sensitive to temperature and humidity. Extreme weather may cause equipment failure, increase operating costs, and reduce financial losses.
Extreme weather short-term Strengthen emergency drills; regularly check for hidden dangers in production and operation facilities, and promptly upgrade experimental data loss; the cold chain transportation system may be interrupted due to disasters, causing vaccine failure. Upstream and downstream business income
Renovate facilities and equipment; make daily reserves of disaster prevention and reduction materials. Water resources Water shortages in major production bases
Chronic risks Short-term Self-operation Increase water costs Carry out water conservation, water resource recycling, etc. Shortage could lead to higher water prices
Environmental regulations: The governments where the business is located will implement more stringent environmental regulations in the future, which will increase operating costs and reduce financial emissions. Pay close attention to and strictly abide by laws and regulations related to carbon emissions and carbon trading, and improve their own operations.
Tighter and looser restrictions and emission quotas will be set to increase long-term business income and improve the company's low-carbon development and climate risk management and control levels. Transformation risk policy risk green
Major export markets have begun to require carbon footprint certification of vaccine products, adding new compliance requirements for own operations, increasing compliance costs and lowering finances.
Supply chain Mid-term Continue to promote the establishment of a carbon footprint management system covering the supply chain. Expenditure Upstream and Downstream Impact
supervision
interests
Increased compliance costs, lower financial
Relevant parties Increasingly stringent environmental performance disclosure requirements increase the related compliance costs of maintaining or improving reputation. Short-term Own operations Monitor local market regulatory requirements and disclosure requirements and carry out compliance work. influence
Expectation
Products/Services Green Medical The global medical and health industry is accelerating its environmentally friendly transformation, and the terminal market is demanding low-carbon packaging in the short term. Downstream, it will increase product sales revenue and continuously expand application scenarios, etc.
Opportunities Product Demand Continued growth in demand for materials, recyclable medical consumables Financial Impact
opportunity
Resource efficiency Use recycling technology to recycle materials and improve product process design to reduce the use of raw materials in the short term and reduce the purchase of raw materials. Product design is streamlined; promote circular economy with upstream and downstream partners and consumers. Upstream
Opportunities to reduce carbon emissions from the extraction and production of materials while reducing the cost of sourcing virgin materials in the medium term Enable a circular economy
Impact, Risk and Opportunity Management Metrics and Targets
In order to effectively prevent climate-related environmental emergencies, improve emergency response capabilities, and reduce the environmental impact caused by climate risks, the company attaches great importance to the establishment of emergency plans for environmental emergencies. During the reporting period, the company continued to deepen its response to climate change. On the one hand, it increased the publicity and promotion of green and low-carbon concepts, and relied on diversified communication channels and innovative publicity methods to establish and implement emergency plans for environmental emergencies for enterprises and institutions in the Torch factory area on August 24, 2023; on November 25, 2024, it completed the emergency plan for enterprises and institutions in the Excellence factory area. and green development knowledge to enhance the whole society's awareness and participation in green and low-carbon development; on the other hand, we actively work with partners, industry associations and other parties to gather and coordinate the emergency plan filing for environmental incidents, achieve full coverage of emergency filings in all factories, and provide scientific guidance and process compliance for responding to various climate-related environmental emergencies. Join forces to jointly promote the development of green and low-carbon undertakings, fulfill environmental responsibility with practical actions, and contribute corporate strength to building a beautiful China and promoting global climate governance.
25 26 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
build unity
Let’s go to a better future together
Protect employees’ rights and interests 29
Implement safe production 37
Spreading hope for charity 40
SDGs response:
27 28 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
protect
The company attaches great importance to human resource management risk identification, and the risk of brain drain is a key concern of the company. The company system comprehensively monitors the brain drain situation, pays more attention to departments with prominent brain drain problems, and adopts on-site interviews and employee resignation interview forms for resigned employees to gain an in-depth understanding of the reasons for resignation, timely discovery and solution of problems, and employee rights and interests.
The company actively adopts measures such as expanding the space for talent development and implementing precise and effective incentives to coordinate and manage the problem of brain drain.
In 2025, the company did not receive any human rights-related
During the reporting period
complaints, no major labor disputes occurred, and effective maintenance of
equal employment
It maintains a harmonious and stable labor-management relationship and demonstrates the company’s
people
Baike Biotechnology has always adhered to the concept of equal employment, strictly abided by the "Labor Law of the People's Republic of China", "Labor Contract Law of the People's Republic of China" and other relevant national laws and regulations, and actively acted as an enterprise with equal employment and respect for human rights. report
Number of new employees joining
In response to the relevant requirements of the Universal Declaration of Human Rights and the International Convention on Human Rights, and strictly abide by the provisions of the International Labor Organization (ILO) and the United Nations Global Compact in the field of human rights, the number of new employees will be 108 during the period, including males.
Diversified development and equal opportunities run through the entire employment process. The company resolutely prohibits any form of employment discrimination, opposes forced labor, harassment and abuse and other violations, and eliminates the use of children. 76 people and 32 women provide services for the company’s production and operations.
employees, treat employees of different nationalities, races, genders, religious beliefs and cultural backgrounds fairly and fairly, effectively protect the legitimate rights and interests of every worker, and fulfill corporate social responsibilities. Strong guarantee. Among them
In order to standardize the employment management process and ensure the implementation of equal employment, the company formulates scientific and reasonable annual employment plans based on its own development strategy and actual operations, and always adheres to the "based on
76 In line with the development concept of "people-oriented" for new female employees, the "Standard Operating Procedures for Employee Recruitment" was issued to clarify the recruitment process, standards and requirements, effectively ensuring the rationality and standardization of the recruitment work.
people
sex and efficiency. At the same time, the company actively expands recruitment channels, builds a diversified and all-round talent introduction system, and combines the dual-track recruitment strategy of school recruitment and social recruitment to build a system
Number of new male employees in 2025
Integrate the talent selection mechanism and continuously optimize and adjust the recruitment model according to market changes and corporate development needs to ensure that talent introduction is synchronized with the company's development.
male new employee
people
Campus Recruitment Complaints
Number of new female employees
Human rights related complaints
The company innovates the school-enterprise cooperation model, accurately meets the talent training needs of colleges and universities, establishes a long-term and stable school-enterprise cooperation mechanism, and realizes the realization of enterprise-enterprise cooperation.
Two-way empowerment of universities. During the spring recruitment period, the company carried out publicity and exchange activities in many colleges and universities in the interactive form of "Brothers and Senior Sisters Talk".
Get closer to students and convey corporate philosophy and employment needs; during the autumn recruitment period, we conduct public welfare courses and gather students in many target colleges and universities.
Professional sharing on resume writing, interview skills, career development planning, etc., to provide students with targeted employment opportunities from the perspective of corporate employers.
Industry guidance. A series of measures not only consolidated the good cooperative relationship with teachers and students of universities, but also effectively maintained the company’s employer brand image and became a
It has successfully attracted a group of high-quality and high-potential university talents to join.
Salary and benefits
Baike Biotechnology has always regarded the construction of the salary and benefits system as an important starting point to attract high-quality talents, stimulate employee vitality, and enhance the core competitiveness of the company. It continues to improve the salary and benefits guarantee social recruitment system, strengthens the incentive effect of salary and benefits, helps the company's industry competitiveness improve and high-quality sustainable development, and achieves two-way empowerment and common growth of the company and employees.
The company strictly implements the "Standard Operating Procedures for Employee Recruitment" and has established a wide range of services covering online recruitment platforms, on-site job fairs, headhunting services, etc.
In order to ensure that the salary system adapts to the current development needs of the company, the company has formulated a "Salary Management System" to widely absorb high-quality talents in the industry through a diversified recruitment channel system. In 2025, the company's recruitment work will closely focus on talent strategy and business development.
Build a scientific and reasonable salary distribution mechanism and a management mechanism that pays equal attention to incentives and constraints, consolidate the development of salary management work to meet demand, continue to optimize the recruitment process, improve the professional efficiency of recruitment, focus on examining candidates' professional qualities, comprehensive abilities and the basis for fair payment and quality work, and promote the development of salary management in a standardized and scientific direction. At the same time, the company continues to optimize the fit of salary management with company culture to ensure that the introduction of talents is highly consistent with the company's development strategy. The entire recruitment and employment process is compliant, transparent, fair and
The system adheres to the principle of "fair pay, good rewards for good work", and is based on job value, personal performance, professional ability, etc., which not only ensures the timeliness of recruitment work, but also achieves a dual improvement in the quality and efficiency of talent introduction, and injects high-quality development into the company's development.
The core factor is to establish a reasonable salary distribution system to achieve an accurate match between employee capabilities and salary value, and tap into strong talent motivation.
Effectively stimulate employees' work enthusiasm and endogenous motivation. Salary Management System Principles
29 30 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
In order to further strengthen the incentive effect of remuneration, the company directly links employee remuneration with individual performance.
In order to further improve the grade management system and smooth the channels for talent development, the company has linked the "employee job grade appointment office" and implemented a "salary package" management policy to link bonuses, performance pay and personal performance.
The "Salary Package" Management Policy is based on the Law of the People's Republic of China, which clarifies the qualifications and organizational procedures for employee promotions, and sorts out and standardizes management job levels.
The horizontal classification and vertical ranking evaluation results are closely integrated to truly realize "more work, more reward, excellent performance and excellent reward", and effectively combine
Correspondence with technical position grades. At the same time, it combines key business needs, job value differences, and regardless of the fairness, efficiency, and motivation of salary distribution. To protect the "salary package" policy
The differentiated requirements for talent quality in the same job sequence and different majors are implemented smoothly and efficiently in accordance with the "horizontal sequence and vertical ranking". The company actively guides and reviews various departments to formulate scientific and cooperative policies.
Based on the principle, two horizontal sequences are divided into "management sequence-professional sequence", and an exclusive hierarchical structure is designed for each sequence, and the performance appraisal plan, annual bonus distribution plan and related implementation details are managed throughout the process.
Clarify the promotion paths and evaluation criteria for each sequence and level, and provide employees with fair, equal, clear and accessible
Management sequence Professional sequence follow-up and put forward targeted opinions and suggestions to ensure that each department accurately grasps the core essence of the policy
Development opportunities and promote the coordinated development of management and technical talents at all levels.
personal performance bonus,
God, strictly implement all requirements.
performance pay
Assessment results
In terms of talent cultivation system construction, the company has built a comprehensive and diversified employee cultivation system by improving institutional guarantees and enriching cultivation forms. The company has successively formulated the "Talent Cultivation Management System", "Talent Echelon Construction Management System", "Management Trainee Introduction and Cultivation Management System" and "Training Implementation Standard Operating Procedures" to provide standardized and standardized institutional support for talent cultivation; at the same time, based on the individual development of employees In order to meet individualized needs, the company implements a multi-dimensional training system, encourages employees to continue their studies and improve independently, and helps employees realize that in terms of salary package distribution and total control, the company strictly controls the total salary package of each department within the budget through accurate calculation and reasonable coordination, and at the same time implements a differentiated management model.
Match personal abilities with job requirements at the same frequency.
Achieve instant motivation for employees. This refined salary management and control method not only fully embodies the principle of fair and just distribution, but also effectively stimulates employees' work enthusiasm and initiative.
nature and creativity, help improve employee work efficiency, stimulate innovation and learning motivation, further strengthen talent retention, promote organizational development, and inject strong force into the long-term sustainable development of the enterprise.
Big kinetic energy.
development training
By improving the rank system, smoothing promotion channels and building diversified cultivation, Baike Biotechnology
mechanism to empower employees to grow in an all-round way and coordinate the promotion of management and technical talents at all levels
development and reserve core strength for the long-term development of the enterprise. Develop and evaluate company strategy and business
To meet development needs, regularly conduct inventory of talent teams in each system, based on performance, capabilities and
Evaluate and classify based on multi-dimensional criteria such as potential, and accurately identify gaps and developments in talent capabilities.
In order to accurately cultivate key talents at all levels and consolidate the construction of the talent echelon, the company has established diversified talent training projects, including pilot classes, elite classes, eagle classes, youth training classes, and young seedling exhibition needs. Targeted design and implementation of training and development projects systematically improve the overall quality of talents.
Five special shifts of the class, as well as four key talent training projects of Locomotive, Qinglan Class, Polytechnic Class, and Qineng Group, will carry out all-round, product chain knowledge, full life cycle management capabilities and business cognition levels for management and technical reserve backbone personnel at all levels, and will take stock of the results
Systematically cultivate and exercise to comprehensively improve the professional abilities and comprehensive qualities of key talents. For master's and doctoral management trainees, the company adopts a personalized training model, formulating personal development plans, planning professional growth paths and implementing precise incentives through mentorship
Core links such as apprenticeship pairing, job rotation internships, and stage reports help them quickly integrate into the company culture, master professional skills, and adapt to job needs, and build a core basis for retention for their future career development, thus building a closed loop of "evaluation-development-retention" and continuously strengthening the
Basics.
Improve organizational capabilities and talent reserves. development retain
Diversified Talent Training Project
The company strictly regulates employee hierarchical management and promotion paths. Based on the "Employee Technical Position Grade Evaluation and Recruitment Process" and the "Employee Position Grade Appointment Methods", the company carries out orderly adjustments to job positions and other special shifts and key talent training projects. In terms of job sequence setting, two development channels, management and technology, are clearly divided. Each channel combines job responsibilities and functions and is refined into six levels, in order:
General manager, deputy general manager, chief scientist level, director level, middle manager level, supervisor level, technical/management positions, other positions; in the process of rank evaluation, the company combines the establishment regulations, leadership flight, elite class, young eagle class, youth training class, young crop class, locomotive, blue class, talented class, enabling group planning, job setting and management needs, and refers to the comprehensive evaluation of employees in the previous year, and standardizes the evaluation of technical and management positions to ensure fairness, transparency and compliance in the evaluation work.
31 32 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
In 2025, the company's development and training work has achieved remarkable results. Through various trainings throughout the year, 15 employees were assisted to obtain certificates from authoritative institutions; they actively participated in the declaration of talent projects in Jilin Province and organized them in an orderly manner.
Organized professional title review work, among which 3 people obtained senior professional titles, 8 people obtained intermediate professional titles, and 1 person obtained assistant-level professional titles, which effectively improved the professional qualification level of employees and further improved the company. The company strictly abides by relevant national and local laws and regulations, and pays full pension insurance, unemployment insurance, and medical insurance for employees in accordance with the law, thus improving the company's talent echelon structure and injecting strong talent power into the company's high-quality development. Work-related injury insurance, maternity insurance and housing provident fund effectively build a solid social security bottom line for employees and relieve employees of their worries. At the same time, lay the foundation
In line with the nature of the position and the characteristics of the work, the company regularly completes the working hours approval and filing procedures with the Ministry of Human Resources and Social Security every year to scientifically coordinate the work and rights protection of employees.
The pace of life ensures employees’ work-life balance; employees are entitled to statutory paid holidays in accordance with the law, covering statutory holidays, annual leave, wedding
15 3 8 1
Leave, bereavement leave, maternity leave, sick leave, personal leave, work injury leave, etc., fully protect employees’ rights to rest and vacation.
employees employees employees employees
Obtain certificates from authoritative organizations Obtain senior professional titles Obtain intermediate professional titles Assistant-level professional titles
The company takes into account both practicality and humanity, and continues to enrich welfare forms. In terms of daily benefits, free working meals and free shuttle buses are provided to all employees to effectively solve the commuting and dining problems of employees and improve their happiness at daily work; in terms of health care, we regularly organize diversified activities for all employees
New employee training, professional skills training, health check-ups for employees, timely understanding of employees’ physical conditions, and condolence benefits provided to employees who are sick and hospitalized and those who have experienced family changes.
Gold, convey the warmth of the company. During traditional festivals, the company insists on carrying out holiday condolences, and provides comprehensive and in-depth training to employees during Dragon Boat Festival, Mid-Autumn Festival, etc., covering company management systems, corporate culture and GMP. Company-level training is an important part of the training system. This level of training includes holiday gifts or subsidies; employee birthday benefits are implemented on a regular basis, covering all employees, and each employee is given exclusive birthday wishes. Chemicalization, safety knowledge, GMP series knowledge training, etc. Covering the entire life cycle of quality management, quality risk management, and pharmaceutical regulations
Key areas include interpretation, pharmacovigilance knowledge, and sterile manufacturing control. this
In addition, the company also provides department public knowledge training and job professional practical training.
training, as well as high-quality external industry policies, regulations and professional knowledge training. for
In order to promote technical exchanges and the sharing of cutting-edge professional knowledge, the company also regularly holds events to accurately meet the needs of employees and convey humanistic warmth. On the eve of the Spring Festival, a special condolence activity of "care and warmth" for employees in need was carried out, and a doctoral salon was held. A total of 16 people were assisted, effectively resolving the difficulties of employees in need and solving practical difficulties; the company continued to implement the employee family consolation system, and a total of 31 people were visited throughout the year, providing timely care and support when employees encountered family troubles. For female employees, the “March 8th” International Working Women Special Project
During Women's Day, the company's labor union carried out condolence activities with the theme of "Innovation and striving to celebrate March 8th, heroines write new chapters", benefiting 517 female employees with care and assistance
workers, send flowers and gifts to show respect and care for female employees. At the same time, the company focuses on improving employees’ emergency response capabilities and organizes operation and management ability training and general management training.
A special cardiopulmonary resuscitation (CPR+AED) training was carried out for “Everyone learns first aid, and first aid is for everyone”. 52 employees passed the exam and obtained certificates, which effectively improved employees’ emergency self-rescue and mutual rescue capabilities and protected employees’ lives, health and safety.
Focus on leadership and management ability training, including performance management, grass-roots training for R&D, production, quality, marketing, functional and senior managers
Management cadre training, etc., aims to improve employees’ management literacy and teamwork. The company provides general management knowledge training on an online learning platform.
capabilities such as operation and efficiency improvement. To meet the learning needs of employees at different levels.
Case: Baike Biology held a condolence event with the theme of "Innovation and Striving to Celebrate March 8th, Heroines Write New Chapters"
On the occasion of the 115th "March 8th" International Women's Day, in order to enrich the spiritual culture of employees, care for female employees, and create a joyful and warm holiday atmosphere, the Baik Bio Trade Union Committee sent flowers and gifts to female employees, benefiting 517 female employees, and sent holiday blessings and care to female employees.
Employee care
Baike Biotechnology has always adhered to the "people-oriented" development concept, integrated employee care into every aspect of daily operations, and built a comprehensive, multi-level, and normalized employee care system.
system, from basic security, holiday balance, welfare provision, special assistance to entertainment enrichment, comprehensively protect employees' rights and interests, enhance employee happiness and sense of belonging, and enhance team cohesion
force to help enterprises and employees grow together.
33 34 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Case: Baike Bio organized a special training on cardiopulmonary resuscitation (CPR+AED) of "Everyone learns first aid, first aid is for everyone" Case: Baike Bio held the 6th Employee Fun Sports Meeting
In 2025, the labor union of Beike Biotech organized a special cardiopulmonary resuscitation (CPR+AED) training for "Everyone learns first aid, and first aid is for everyone", and 52 people passed the exam and obtained the certificate. On September 28, 2025, in this crisp autumn season, the sixth employee fun sports meeting of Beike Biotech kicked off with enthusiasm.
book to effectively improve employees’ emergency self-rescue and mutual rescue capabilities
Fun sports combine competition with entertainment, focusing on employees' participation and mutual cooperation. The competition events are rich, interesting and cooperative, covering a total of 10 events including Penguin Walk, Lazy Bicycle, Transposition, Tennis Relay, Multi-person Ring Pass, Invincible Hot Wheels, Crossing the River by Touching Stones, Big Rope Jumping, Ring Relay, and Tug of War, allowing all employees to feel the joy of sports in interesting competitive activities.
This fun sports meeting allows employees to realize that in order to win as a team, everyone must put in 100% effort, think in one place, work hard in one place, cooperate closely and support each other to form a powerful force. In the sports competition, the company's cohesion and team spirit are enhanced, and the energetic spirit and good moral style of our Baike Bio employees are demonstrated. We must work together as one, exert strong synergy, and jointly write a new chapter in the development of Baike Biology.
The company actively creates a lively, progressive, united and cooperative team atmosphere and organizes various special cultural and entertainment activities. During the Lantern Festival, "golden
The themed activity "Snake Yue Dances and Guessing Lantern Riddles" creates a strong traditional festival atmosphere through interactive links such as fun lantern riddle guessing, and enhances the relationship among employees.
Entertainment life
communication; held the 6th Staff Fun Sports Meeting, set up a number of interesting and collaborative competitions, and guided employees to actively
Participation effectively enhances the cohesion and centripetal force of the employee team, allowing employees to relax physically and mentally and enhance friendship after work.
Case: Baike Bio launched the theme activity of "Golden Snake Yuewu Guessing Lantern Riddles"
On February 12, the Baike Biological Trade Union Committee held meetings at the Excellence Factory and the Torch Factory at the same time.
Carry out the fun lantern riddle-guessing activity "Have a Happy Lantern Festival".
democratic management
After the activity started on time, everyone actively participated and competed with each other in wisdom and skills.
Knowledge, laughter, and joy made the scene a joyful and peaceful scene. Baike Biotechnology actively unblocked democratic management channels, improved the democratic management mechanism, and effectively guaranteed the democratic rights of employees by standardizing the operation of the employee representative conference and conducting employee director elections in an orderly manner. To achieve benefits, strengthen the enterprise supervision system, build harmonious labor relations, and lay a solid institutional foundation for the sustainable development of enterprises.
This event was successfully concluded under the careful preparation of the trade union committee, creating a warm atmosphere. In order to solidly promote the implementation of democratic management and achieve results, the company will organize an employee representative conference in 2025, focusing on the election of employee directors. The election of employee directors is a perfect, joyful and peaceful holiday atmosphere for the company. It not only inherits traditional holiday folk customs, but also improves the corporate governance system and deepens the important practice of democratic management. It not only effectively guarantees the democratic election and democratic supervision rights of all employees, allowing employees to truly participate in corporate management, but also stimulates employees' enthusiasm for participating in company activities. It not only enriches employees' professional knowledge, but also further strengthens the internal supervision mechanism of the company, promoting corporate decisions to be more in line with the interests of employees and the actual development of the company.
Yu cultural life has also increased emotional exchanges among employees.
While deepening democratic management, the company's labor union effectively plays the role of bridge and link, accurately cares for employees, builds a warm and protective line of defense, deeply integrates democratic management and employee care, further builds employee consensus, enhances team centripetal force, and promotes the coordinated advancement of corporate democratic construction and employee development.
35 36 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
implement
strategy
Production safety: The company attaches great importance to the standardization and standardization of production safety, and has successfully obtained the occupational health and safety management system certificate and the third-level safety production standardization certificate, marking that the company's safety production management level has reached industry standards and achieved standardization, normalization and scientific management and control of safety production work. At the same time, the company has formulated the "Safety Risk Hierarchical Control and Hidden Hazard Investigation and Governance System Manual", conducts comprehensive inspections and special inspections on production safety on a regular basis, accurately detects various safety hazards and promptly rectifies and eliminates them, preventing safety accidents from the source; every year, it entrusts a third-party agency with corresponding qualifications to conduct occupational health hazard factor testing at the production workplace to fully understand the safety status of the working environment and effectively protect the occupational health of employees; strictly in accordance with relevant regulations, fully distribute special labor protection supplies to employees, strengthen workplace safety protection, and reduce operating safety risks.
Baike Biotechnology always adheres to the safety production policy of "safety first, prevention first, comprehensive management", and integrates safety production into
As the bottom line project for the high-quality development of enterprises, production safety must be strictly implemented in accordance with the "Work Safety Law of the People's Republic of China" and other
Safety first, prevention first, comprehensive management, impact, risk and opportunity management
Relevant national laws and regulations, through improving the institutional system, improving the organizational structure, and strengthening management and control measures, we have established a comprehensive
A comprehensive, full-process, and full-coverage safety production management system effectively prevents safety risks and eliminates safety incidents. The company implements the "Safety Production Law of the People's Republic of China" and other laws and regulations, and formulates the "EHS Responsibility System", "Safety Education and Training System" and "Safety Hazard Inspection and Management System" to build a solid safety defense line for enterprise development. "Fire Safety Management System", "Special Labor Protection Equipment Management System", "Construction Project Construction Safety Management System", "Accident Report Investigation and Handling Management System", "Special Safety Production Policy"
The "Operation License Management System" and "Occupational Disease Hazard Monitoring and Evaluation Management System" stabilize the safety line of defense for the company's development through system construction.
governance
In terms of organizational system guarantee, the company has set up a complete safety production management organizational structure and established a safety production committee as the highest leadership body for the company's safety production work.
Establish a responsibility system of “top-level planning and layer-by-layer implementation”. The committee is chaired by the general manager, with senior management members as deputy directors and middle-level managers from each functional department as members.
Composed with the same composition, it is mainly responsible for reviewing and issuing the company's safety production-related policies and development directions, coordinating and promoting various safety production tasks, and ensuring that safety management requirements cover all employees horizontally.
Functional departments, extending vertically to the end of each position, providing a solid organizational guarantee for the company's production and operation activities.
Based on its own production and operation characteristics, the company has built a systematic and standardized safety production management system, and has successively formulated the "EHS Responsibility System" and "Safety Education and Training System"
"Safety Hazard Inspection and Management System", "Fire Safety Management System" and other special systems cover safety education, hidden danger investigation, fire safety, special operations, occupational diseases
In all areas and links of production safety, including protection and accident handling, the safety production responsibilities, operating standards and control requirements of each position are clarified, and all aspects of safety production are ensured with rigid institutional constraints.
The work is carried out in an orderly manner and lays a solid institutional foundation for the company's safe production.
In terms of accident emergency response and management, the company strictly complies with the "Regulations of the People's Republic of China on Work-related Injury Insurance" and other national regulations, and improves the "Accident Report Investigation and Handling Management System" based on the actual situation of the company, clarifying the procedures and requirements for accident reporting, investigation, and handling, and strictly follows the "Four Don't Let It Go" In accordance with the principle of (no letting go until the cause of the accident is identified, no letting go until the responsible person is dealt with, no letting go until the corrective measures are implemented, and no letting go until the relevant personnel are educated), comprehensive cause analysis of various accidents, serious investigation and handling, summarizing the lessons learned from the accident, optimizing prevention and control measures, and preventing recurrence of similar accidents. If a work-related injury accident occurs, relevant departments will rush to the scene as soon as possible to carry out disposal and investigation work, promptly send injured employees for medical treatment, and apply for work-related injury identification and labor ability appraisal according to standardized procedures to effectively protect the legitimate rights and interests of employees and minimize losses caused by accidents.
37 38 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Metrics and Goals
The company has passed the occupational health and safety management system certification. In 2025, no production safety accidents occurred.
sow
Public welfare hope
Case: Fire safety training drill in Torch Factory on March 27, 2025 Case: Comprehensive fire safety training drill in 2025 Production Safety Month
social welfare
Baike Biotech always keeps its corporate social responsibility in mind, actively participates in public welfare undertakings, focuses on the health protection of the elderly, and uses practical actions to convey warmth and fulfill its responsibilities.
During the reporting period, the company used the special public welfare project of "Guarding the Silver Age, Preserving Love First" as a carrier, and joined hands with the China Aging Development Foundation to sign a contract to donate a total of 20,000 live attenuated herpes zoster vaccines to help improve the health protection level of the elderly. As of the end of the reporting period, this special public welfare project has successfully completed the donation of 9,143 vaccines. The public welfare results have been remarkable and the care for the elderly has been truly implemented. In 2025, the company will continue to increase its investment in public welfare and carry out all-round public welfare assistance work. The public welfare investment throughout the year covers funds. Case: Fire safety training drill in the vaccine room three of the Excellence Factory on April 11, 2025. Case: 2025 Safety Production Month Safety Competition
With multiple dimensions of funds and materials, a total of 74,800 yuan was donated to external parties, a special investment of 200,000 yuan in public welfare funds, and a discount of 12.5168 million yuan in donated materials. Various public welfare investments were accurately implemented and the results were promising. A total of 9,143 people were benefited from public welfare assistance throughout the year.
20,000 9,143
As of the end of the reporting period,
A total of signed donations of live attenuated herpes zoster vaccine were signed. This special public welfare project has successfully completed the donation of vaccines.
2025
7.48 20 1,251.68 9,143
Case: Baike Biotech launches deviation practical operation competition
Ten Thousand Yuan Ten Thousand Yuan Person
Cumulative external donations, special investment of public welfare funds, donated materials discounted, cumulative benefits of public welfare assistance throughout the year. In order to improve the processing ability of production operators after the occurrence of deviations, enable production front-line employees to correctly understand the hazards and impacts of deviations, and effectively reduce the probability of recurrence of deviations,
The company will hold a "Deviation Practical Operation Competition" in October 2025 in which all workshops and equipment power departments will participate.
39 40 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Case: "Protecting the silver age, safeguarding love first - Shingles prevention and control action" charity donation ceremony was held in Changchun Case: Beike Biotech Exhibition in Frankfurt: Connecting the world with new opportunities
In September 2025, the "Protecting the Silver Age, Protecting Love First--Herpes Zoster Prevention and Control Action" charity donation event co-sponsored by the China Aging Development Foundation and Beike Biotechnology attracted the attention of the global pharmaceutical industry in Frankfurt, Germany - the most authoritative event in Europe was successfully held in Changchun, Jilin. Beike Biotech signed a contract to donate 20,000 herpes zoster vaccines to the China Aging Development Foundation, and the Pharmaceutical Raw Materials Exhibition (CPHIFrankfurt) to support the effectiveness of herpes zoster in the elderly came to a successful conclusion here. prevention work. Baike Biotech presented the company's three core products: live attenuated chickenpox vaccine, live attenuated freeze-dried nasal spray influenza vaccine and live attenuated herpes zoster vaccine. The mission of this exhibition is not only to deepen the recognition of core products in the international market, but more importantly, to comprehensively demonstrate the huge potential of the company's research pipeline and explore the possibility of multiple cooperation models.
CPHI FRANKFURT
Frankfurt, Germany—Europe’s most authoritative pharmaceutical raw materials exhibition
medical accessibility
Case: Gathering momentum in Kuala Lumpur to start a new journey of cooperation in Southeast Asia - Baike Biotech makes its debut in Southeast Asia. Baike Biotech actively responds to the joint construction of the "One Belt, One Road" initiative. Based on its own development advantages and relying on global layout planning, it actively integrates into the industrial development pattern of countries along the route and deeply participates in the process.
Industrial exchanges and cooperation among countries along the Belt and Road, using biomedical expertise to assist the development of infectious disease prevention and control in countries along the Belt and Road, and practicing the concept of a human health community.
From July 16 to 18, 2025, the Pharmaceutical Ingredients Exhibition Southeast Asia (CPHI South East Asia) was held in Kuala Lumpur, Malaysia. In recent years, the company has focused on international development and actively built a bridge for external exchanges and cooperation. It has participated in a series of key international exhibitions and economic and trade activities, covering the world's pharmaceutical raw materials.
The company has three star products, chickenpox live attenuated vaccine, freeze-dried nasal spray live attenuated influenza material, European exhibitions (Italy, Germany), Southeast Asia exhibitions (Malaysia), Egypt International Medical Exhibition and Tanzania economic and trade exchange activities and other important platforms. Currently successfully
Vaccines and live attenuated herpes zoster vaccine made a shining appearance at this exhibition. During the exhibition, Pakistan, Bangladesh, Indonesia and other countries along the "Belt and Road" exported chickenpox vaccines. The products were recognized by the local market and users due to their reliable quality, and effectively provided
During the period, Baike Bio's booth attracted the attention of many international dealers and received local infectious disease prevention and control products to provide product support.
Many high-quality customers from Myanmar, Malaysia, Indonesia, Germany and other countries discussed in depth product advantages and cooperation opportunities. At the same time, the team took the initiative to visit a number of Southeast Asian pharmaceutical distributors to achieve precise docking and promote product promotion. Case: Deepen international exchanges and jointly promote the cooperative development of biopharmaceuticals - Beike Biologics receives the delegation of envoys to China
Market expansion injected strong impetus.
On December 18, as an outstanding enterprise representative in the field of biopharmaceuticals, Baike Biotech received
Received a delegation of diplomatic envoys from many countries stationed in China organized by the Ministry of Foreign Affairs of the People's Republic of China. This CPHI SOUTH EAST ASIA
This event aims to strengthen international communication. Through a comprehensive and systematic introduction, the company
Guests at the conference demonstrated their R&D strength, industrial layout and innovation in the field of biopharmaceuticals. Kuala Lumpur, Malaysia-Pharmaceutical Raw Materials Exhibition Southeast Asia Exhibition
New results.
41 42 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Toughness and ingenuity
Light up the glow of health
Adhere to innovative research and development 45 Adhere to scientific and technological ethics 49 Stabilize supply security 51 Improve product quality 53 Protect data security 56
SDGs response:
43 44 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
The company continues to delve deep into core technology areas and actively participates in the "Technical Guidelines for the Detection of Human Respiratory Syncytial Virus Neutralizing Antibodies" and the "Early Clinical Research Specifications for Preventive mRNA Vaccines"
Compilation work. As a participant and promoter of technological innovation in the industry, the company relies on its technological accumulation and practical experience in related fields to deeply participate in the content discussion, indicator setting and text improvement of the group standard, and integrates its own technological accumulation and industry practice results into the standard system, providing strong support for the scientificity, practicality and forward-looking nature of the standard. Innovative research and development
strategy
In terms of R&D planning, the company follows the medium- and long-term strategic plan as a guide, and jointly works with various R&D-related business sector departments to jointly complete the gradient layout of the company's R&D projects. Based on industry development trends and actual corporate needs, the company updates the layout content from time to time and reports it to the company to ensure that the layout of R&D projects is scientific and reasonable and meets development needs.
governance
In terms of innovative R&D governance system, the company has established a separate drug research institute for the internal R&D system, which is directly managed by the director of the drug research institute. The Pharmaceutical Research Institute has a scientific department and a research and development management level. The company has established a "Project Management Committee", which is mainly responsible for review and
Project Management Department, Laboratory Management Department, Clinical Research Department, Registration Department and various project teams. Determine the company's technology development plan and related policies, and provide professional advice for R&D work
and technical guidance; at the same time, the committee focuses on major scientific and technological decisions and key product development, and is responsible for review and decision-making.
project management
Promote drug research institutes and technical projects, accurately solve core technical problems in the research and development process, and ensure the project management committee's company's scientific and technological development plan
committee
R&D and innovation work are advancing steadily. In terms of R&D evaluation, the company has established a normalized tracking and related policy mechanism to track and promote key projects on a quarterly basis and prepare a life-cycle report for the project.
Cycle progress schedule to monitor project progress in real time.
Science Department Project Management Department Laboratory Management Department Clinical Research Department Registration Department Various Project Teams
The responsibilities of each department are clear: the Science Department is responsible for basic research exploration, principle verification, molecular screening, scientific guidance, etc.; the Project Management Department is responsible for the daily progress management of the project, technical support. The normalized tracking mechanism tracks and promotes key projects on a quarterly basis, and prepares the project's full life cycle schedule to keep track of the project progress in real time. The Laboratory Management Department is responsible for the laboratory's business plan, budget, work summary, laboratory management, etc.; the Clinical Research Department implements the implementation of products that have obtained clinical approval.
Clinical trial work; the Registration Department is responsible for clinical trial applications, marketing authorization applications, supplementary applications and re-registration applications for drugs.
On the basis of insisting on independent research and development, the company attaches great importance to the construction of an innovative environment. In 2025, it was successfully recognized as a national enterprise technology center, and its innovative research and development strength was authoritatively recognized. Science Department Project Management Department Laboratory Management Department Clinical Research Department Registration Department
At the same time, the company actively carries out industry-university-research collaborative innovation and has established stable technical exchanges and cooperation with well-known scientific research institutes such as Jilin University and the Institute of Pathogen Biology of the Chinese Academy of Medical Sciences. In addition, it has further improved its technical strength and scientific research level by introducing advanced technologies from international partners such as Intravacc and NIH in the Netherlands.
Daily progress management of research and exploration projects Laboratory business plan Application for clinical trials of drugs that have obtained clinical approval documents
products
Implement clinical trials
Proof of principle Technical support Budget Marketing authorization application
... ...Molecular Screening Work Summary Supplementary Application
project management committee
Scientific guidance, laboratory management, re-registration application, technical exchange and cooperation, introduction of advanced technology
The company adopts a management model that combines goal management and project management, clarifies the division of responsibilities of each department and position, integrates internal and external innovation resources, and improves corporate technology. As a member of the China Vaccine Industry Association, a member of the Jilin Provincial Biological Products Committee, and the leader of the Jilin Provincial Biopharmaceutical Industry Science and Technology Innovation Alliance, the company actively implements the industry innovation system. At the same time, we continue to optimize the innovation management mechanism, revise the "Project Management System" and other management policies, and proactively participate in various industry exchanges and collaborations from R&D project establishment, process control, project acceptance, and post-project evaluation responsibilities. Every year, R&D innovation personnel are organized to participate in relevant academic exchange activities as members, providing R&D personnel with full life cycle standardized R&D behaviors such as learning, growth, and communication. A platform for flow improvement to help the R&D team grasp industry development trends in a timely manner.
45 46 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Impact, Risk and Opportunity Management Case: Co-developing a new chapter and building the Great Wall of Health together - Jiangsu Provincial Center for Disease Control and Prevention and Beike Biotech Public Health Cooperation Company continue to delve into the field of innovative research and development. By continuously promoting technological innovation and product research and development, they have improved the product matrix and enhanced the core competitiveness of the company. Currently, they have successfully sold products to India, Pakistan
Varicella vaccines are exported to countries such as Stanislavia, Bangladesh, and Indonesia, and the products have been widely recognized by the local market for their reliable quality. At the same time, industry technology updates are rapid and research and development
On the afternoon of April 23, the Jiangsu Provincial Center for Disease Control and Prevention and Beike Biotech invested heavily in Nanfa and the cycle was long. The company also faced potential risks such as R&D failure and lagging technology iterations; however, the country’s policy support for the biopharmaceutical industry continued to increase, and residents’ health
A symposium on strategic cooperation was held in Beijing. The two parties have focused on talent training projects, the increasing demand for public health, and the vast international market space under the “One Belt, One Road” initiative, all of which provide good opportunities for the company’s innovative development.
We will conduct in-depth exchanges on topics such as health care capacity building, vaccine research and development and application, and health service innovation, and discuss plans for cooperative development. This meeting established an important platform to promote the high-quality development of the disease control system in Jiangsu Province. It demonstrated that Jiangsu attaches great importance to intellectual property management in public companies, established a "Patent Management Procedure" and a positive attitude towards open cooperation in the health field.
"Patent Application Standard Operating Procedures" to further improve intellectual property management.
In the patent application process, the company implements a strict secondary review mechanism, requiring all applicants
Please pass the "Patent Application Approval Form" and "Technical Secret Disclosure Application Form"
Intellectual Property Management
Double review, and can only be started after final approval by the general manager, effectively guaranteeing the company's Case: Innovation Leads the Future: The 2025 China Vaccine Academic Annual Conference was successfully held, and Beike Biotech demonstrated the confidentiality and safety of the core technologies of multiple star products. In order to improve patent management efficiency, the company introduced
The Incopat patent professional search database can provide powerful global patent search. From November 14 to 16, 2025, the China Vaccine Industry Association (the first) academic support; based on this, the company established a patent pool system that matches the research and development projects. The technical conference and exhibition was successfully held in Xiamen. This conference brought together more than 1,800 representatives from government agencies, scientific research institutes, universities and domestic and foreign vaccine companies to effectively avoid intellectual property risks and provide project leaders with support. More than 130 authoritative experts shared cutting-edge progress in vaccine research and development and disease prevention and control. As an innovative biopharmaceutical company specializing in the prevention and treatment of infectious diseases, Beike Biotech was invited to participate in the conference and focused on demonstrating the clear indicators and goals of three types of Gan20® chickenpox live attenuated vaccine, Ganwu® freeze-dried nasal spray live attenuated influenza vaccine, and Ganwei® live attenuated herpes zoster vaccine.
star product.
In 2025, the company's innovative research and development has achieved remarkable results, successfully obtaining 1 drug registration certificate, obtaining 5 drug clinical trial approval notices, and initiating phase III clinical trials for 2 products.
After testing, two products started phase I clinical trials. As of the end of the reporting period, the company had a total of 6 products under development undergoing clinical research, and its technological innovation capabilities have been significantly improved. In addition, report
During the reporting period, the company was successfully recognized as a national enterprise technology center, the industry-university-research cooperation network was gradually improved, the gradient layout of R&D projects continued to be optimized, and the chickenpox vaccine was successfully exported to multiple countries. Case: "2025 Vaccine and Health Conference" was successfully held in Wuhan. Baike Biotech used innovative technology to assist the integration of medical and prevention in countries along the "Belt and Road", and innovative R&D and international layout have achieved phased results.
From April 19 to 20, 2025, the "2025 Vaccine and Health Conference" opened grandly at the Wuhan International Conference Center. This conference was hosted by the Chinese Society of Preventive Medicine and brought together more than 2,000 experts, scholars and industry elites in the field of vaccines at home and abroad to discuss cutting-edge issues in vaccine research and development, immunization strategies and medical and prevention integration.
1 5 2 2
Item Item Item Beike Biologics made a wonderful appearance with three core vaccines - chickenpox vaccine (Gan20®), freeze-dried nasal spray influenza vaccine (Ganwu®), and herpes zoster vaccine (Ganwei®), creating a drug registration certificate and drug clinical trial approval notice. The product started Phase III clinical trials. The product started Phase I clinical trials.
The strength of new technologies demonstrates innovative achievements in protecting the health of the public throughout their life cycle. Through product display, diverse science popularization and interactive experiences, the exhibition area attracted the attention of many participants and became a highlight of the conference.
47 48 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
The company regularly organizes and conducts training courses covering laboratory animal welfare ethics and regulations, standardized operating practices, animal welfare assessment and other professional content to ensure that relevant personnel are proficient in the necessary professional knowledge and operating skills. At the same time, the company encourages employees to participate in relevant training courses and seminars organized by external organizations, such as various science and technology ethics training organized by the Jilin Provincial Laboratory Animal Society, to continuously improve employees' professional level and ethical awareness. In addition, the company uses special events such as "World Laboratory Animal Day" to carry out various science popularization activities to create a good cultural atmosphere of respecting life and adhering to scientific ethics.
clinical ethics
The company abides by the requirements of science and technology ethics laws and regulations, fully considers ethical factors, standardizes clinical trial operation procedures by improving system construction, regularly analyzes and supervises clinical data, and evaluates clinical trials. Baike Biotech strictly abides by the "Drug Administration Law of the People's Republic of China", "Good Manufacturing Practice for Pharmaceuticals", "Regulations on the Administration of Laboratory Animals" and "Quality Management Regulations for Clinical Drug Trials".
Compliance training results and performance of researchers, and continuous improvement of staff’s clinical ethics awareness and skills.
Standards, "Regulations on the Implementation of Regulations on the Management of Human Genetic Resources" and a series of relevant laws, regulations and norms, integrating scientific and technological ethics requirements throughout the entire process of various related work, and adhering to scientific ethics
Bottom line.
Improve the system, conduct regular analysis, evaluate clinical researchers, and continuously improve employees. Companies that involve scientific and technological ethical issues in animal testing and human drug testing are entrusted to external qualified units to conduct them, and strict requirements are imposed on them to comply with national laws after approval.
Establish and standardize clinical trial operation procedures and supervise clinical data, conduct compliance training results and performance, and conduct relevant research on clinical ethics awareness and skills regulations.
Before the company starts a clinical trial, it must complete the clinical trial protocol, informed consent form (including revised versions) and other relevant research materials.
The entire process will be submitted to the ethics committee of the cooperative unit for systematic review. After obtaining the formal and effective "Ethical Review Approval", the animal welfare system will be standardized.
The project management committee can start the research project and carry out clinical trial-related operations. To ensure that the entire clinical trial process complies with regulatory requirements and ethical standards
The company has established 16 standard operating procedures for clinical trials and strictly follows them in actual operations. Research institutions and clinical trial companies have specially established experimental animal welfare ethics review committees, which are mainly responsible for conducting comprehensive ethical reviews of experimental animal-related projects. The scope of the review covers the sources and species of experimental animals.
On-site management system documents.
Category, grade, quantity, reasons and purposes of experiments, as well as procedures, methods and disposal methods for the use of experimental animals, etc., to ensure that work related to experimental animals complies with ethical standards.
In terms of personnel management, the company has established a complete personnel training system, requiring all personnel involved in experimental animal work to undergo professional training, including experimental animal feeding management.
Management, operating skills, welfare ethics knowledge, etc., can be employed only after passing the assessment. In terms of the breeding and management of experimental animals, the company clearly stipulates the standards for the breeding environment of experimental animals, including
Including temperature, humidity, illumination, wind speed, ammonia concentration and other conditions, while ensuring the quality and stable supply of feed and drinking water. During the entire process of experimental operations, the company has formulated relevant management systems. The company regularly evaluates the compliance training results and performance of clinical research personnel, and continuously improves employees' clinical ethics awareness. Members can manage the construction and management of projects and standardize the operating procedures of the procurement, transportation, feeding, experimental operations, and execution of experimental animals to ensure that every step meets ethical requirements. and skills to ensure that the research process is standardized and orderly and continues to comply with the requirements of the ethics committee. aspects
936 46
In 2025, the company completed a total of 936 laboratory animal welfare ethics reviews, clinical ethics
Reviewed 46 cases, effectively implemented scientific and technological ethics control, and adhered to scientific research and ethics.
principles of parallel development. Animal Welfare Ethics Review Clinical Ethics Review
49 50 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
stable
Impact, risk and opportunity management
Supply security In terms of material management, the company implements full life cycle quality management of materials used from research and development to the production of products on the market in accordance with the "Material Management Procedures". According to the production purpose of the materials, the materials used for the production of marketed products are divided into raw materials, auxiliary materials, direct contact packaging materials, etc.; a material quality risk assessment report is drafted according to relevant procedures, and the materials are divided into five levels: A, B, C, D, and E, and the classification standards for materials at each level are clarified. At the same time, the company has established a complete material procurement process. Each user department puts forward requirements, and the supply chain management department is responsible for centralized procurement. After the materials arrive, the supply chain management department conducts preliminary inspections to ensure that the purchased materials meet quality requirements.
In terms of vaccine storage, transportation and carrier management, the company has formulated relevant procedures such as the "Vaccine Distribution and Storage Carrier Assessment and Management System" and signed a contract with the carrier to entrust the management of cold chain storage and transportation services.
service contracts and quality assurance agreements to ensure the quality, safety and efficiency of vaccine storage and transportation. In order to create a green supply chain, the company selected 30 high-quality vaccine distribution companies through public bidding. Baike Biotech attaches great importance to supply chain management and formulated the "Material Management Procedures", "Material Supplier Quality Assessment Standard Operating Procedures" and "Supplier On-site Audit Standard Operating Procedures" storage carriers, including 2 trunk line carriers and 28 branch line carriers, to carry out product distribution, storage and transportation work in 2025.
and a series of management systems to standardize the operation of each link in the supply chain and ensure the stability, safety and efficiency of the supply chain.
The company will carry out product distribution, storage and transportation in 2025 through public bidding.
In terms of supplier management, the company has established a strict evaluation mechanism and operating procedures to clarify supplier qualifications, selection principles, quality evaluation methods, evaluation standards and approval procedures.
sequence. The Quality Assurance Department implements quality assessments on all material suppliers, and collaborates with relevant departments to conduct on-site quality audits on key material suppliers (especially manufacturers). On-site quality
30 2 28
Quantitative audits need to verify the authenticity of the supplier’s qualification certification documents and inspection reports, and the fulfillment of inspection conditions, and comprehensively review the supplier’s personnel organization, factory facilities, equipment, and materials.
Material management, production process, etc., comprehensively evaluate its quality assurance system, and all on-site audit activities form a written audit report. At the same time, the company is related to raw materials, auxiliary materials, etc., including
High-quality vaccine distribution and storage carriers, trunk carriers, and feeder carriers all sign quality assurance agreements. The agreement is valid for no more than 2 years and will be re-signed after expiration. The suppliers are required to perform compliance management obligations and ensure that the quality of materials is qualified.
Strict evaluation mechanism and operating procedures
Quality Assurance Department implements quality assessment indicators and goals for all material suppliers
In 2025, the company will focus on implementing the localization of materials by collecting domestic supplier information and conducting product performance testing.
Relevant departments carried out on-site quality audits, comparisons, on-site surveys and sample trials on key material suppliers (especially manufacturers), and achieved breakthroughs in domestic substitution in categories such as experimental consumables and reagents. During the reporting period, the proportion of domestic procurement of key materials such as air filters and liquid storage bags increased significantly, which ensured product quality while optimizing
Procurement costs. In 2026, the company will further deepen multi-department collaboration, continue to promote localized substitution, and build a better 0
Safe, efficient and sustainable supply chain system. pieces
Major risks in the supply chain Verify supplier qualification documents and inspection reports Comprehensive review of the supplier's personnel structure, factory facilities and equipment, material management, production process, etc. Quality assurance system
During the reporting period, the company had no major supply chain risk or impact events.
All on-site audit activities result in written audit reports
strategy
The company has established a diversified supplier management strategy, and strives to allocate alternative suppliers for key materials. When selecting suppliers, priority is given to excellent quality systems, good operational management, and good capital transportation.
It is a stable entity and effectively prevents the risk of supply interruption. In addition, the company has established a complete supply chain risk monitoring mechanism to regularly assess and update supply chain risks to ensure risk
Risk management is timely and effective.
51 52 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
In 2025, the company has passed the quality management system certification.
Diligence
Product Quality The "Keywords" for Quality Management of Biological Products
It refers to the degree of a series of inherent characteristics that are consistent with the intended use. According to this, drug quality means that in order to meet the quality
Requirements for the safety and effectiveness of drugs, physical, chemical or biological (Quality) of the product’s ingredients, content, purity, etc.
degree of learning characteristics.
product quality
Quality Management System Baike Bio strictly abides by the "Drug Administration Law of the People's Republic of China", "Vaccine Administration Law of the People's Republic of China", "Drug Production Supervision and Administration Measures" and "Drug Registration Management Office". It refers to the establishment of quality policies and quality objectives, and organized and planned activities to achieve quality objectives.
(QMS) Law, Pharmacopoeia of the People's Republic of China, Good Manufacturing Practice for Pharmaceutical Products (revised in 2010) and their relevant appendices and other laws, regulations and specifications, have passed ISO9001 quality management
Management system certification, integrating quality control throughout the entire life cycle of drugs, and adhering to the bottom line of product quality.
Emphasize the guarantees that should be provided to meet quality requirements. Quality assurance is a broad concept that covers quality assurance that affects product quality
From an organizational structure perspective, all factors of quantity are all measures taken to ensure that a drug meets its intended use and meets specified quality requirements (QA)
The total amount of donations.
The company has established professional quality management departments such as the Quality Assurance Department, Quality Control Department, Animal Experiment Center, and Confirmation and Verification Department to build a complete quality control system. company
Senior managers clarify the quality responsibilities of organizations and personnel at all levels by formulating quality policies and goals, and implement quality plans to ensure that each functional department completes the corresponding quality
quantity goals, and ultimately achieve the overall quality goals of the enterprise. At the same time, a quality manual is formulated to standardize the entire quality control process. Emphasis on quality requirements. Specifically, it refers to the sampling, inspection and review of the quality control of raw materials, packaging materials, intermediates and finished products in accordance with prescribed methods and procedures to ensure that the composition, content, purity and other properties of these materials and products comply with (QC)
Established quality standards
The company has established an independent pharmacovigilance department, which is guided by domestic and foreign regulations and guidelines such as the Drug Administration Law of the People's Republic of China, Pharmacovigilance Quality Management Practices, and ICH Guidelines.
Under this circumstance, comprehensively carry out the full life cycle management of pharmacovigilance, establish a complete pharmacovigilance system, continuously optimize the master document of the pharmacovigilance system, and minimize drug safety risks. As part of the quality management system, it is a basic requirement for drug production management and quality control, aiming to maximize
Good Manufacturing Practice for Pharmaceutical Products
risk, protect and promote public health. According to the "Pharmacovigilance Management Procedures", the company has established an effective communication model between the Quality Assurance Department and the Pharmacovigilance Department. Reduce the risks of contamination, cross-contamination, confusion, and errors during the pharmaceutical production process to ensure continuous and stable production (GMP)
Drugs that meet the intended use and registration requirements.
corporate risk management
Quality activities covering the entire drug life cycle, including drug research and development, production and preparation, packaging and storage, distribution, and raw and excipient materials, packaging and labeling materials used in each stage. Public
The company has established a quality risk assessment team to manage quality risks through risk assessment, risk control, risk review, risk communication and other processes, and uses a variety of auxiliary tools to identify problems.
Correlate issues, clarify risk rating standards, formulate reduction plans for unacceptable risks and track their implementation, review and review all risks regularly to ensure effective risk management.
Case: Baike Biotech grandly held the 2025 annual quality work meeting to comprehensively deepen the full life cycle quality management
On March 25, 2025, the 2025 annual quality work meeting of Baike Biology was held in Beijing.
The company has formulated relevant systems such as the "Drug Recall Management Procedure" and "Drug Complaint Management Procedure". During the reporting period, major safety and quality liability accidents related to products and services occurred.
The energy hall was held grandly, and all the company's level 4 and above personnel attended the meeting. this
The amount of damage involved was 00,000 yuan; the number of products that needed to be withdrawn and recalled due to health and safety reasons was 0, and the percentage was 0%.
The meeting focused on “comprehensive and in-depth implementation of the concept of full life cycle quality management”
As a core topic, it aims to provide guidance for the smooth development of the company's work in 2025.
0 0 0
Solid protection.
Ten thousand yuan pieces %
Product and service-related safety incidents requiring withdrawal for health and safety reasons %
The amount of damage involved in major quality liability accidents and the number of recalled products
53 54 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
protect
customer service
The company has formulated the "Standard Operating Procedures for Handling and Analysis of Product Complaints", "Standard Operating Procedures for Handling Suspected Abnormal Vaccination Reactions in Individual Cases" and "Data Security of Suspected Abnormal Vaccination Reactions"
(AEFI) Compensation Standard Operating Procedures" and other process documents to build a standardized and professional service system.
After-sales service
The company has set up a 400 service hotline with diversion and answering functions to promptly answer various questions of recipients before and after vaccination, reducing the risk of medication errors and improving customer satisfaction.
Baik Biotech strictly abides by the "Data Security Law of the People's Republic of China", "Personal Information Protection Law of the People's Republic of China", "Cybersecurity Law of the People's Republic of China" and other national relevant regulations; the Pharmacovigilance Department is responsible for professional medical review of individual case safety reports and summary analysis reports, and conducts scientific assessment, investigation and compensation lawsuits on AEFI.
Legally, we integrate data security, network security and customer information security management and control throughout the entire business process to ensure data compliance and orderly management.
Ask for response. In 2025, the company will continue to optimize the processes related to AEFI disposal and evaluation, improve the individual case follow-up management mechanism, and maintain medical consultation and complaint services throughout the year.
Zero bad reviews.
Organizational structure
The company has established a network security leadership group headed by the general manager, which is responsible for implementing the government departments’ regulations on network security, customer information security, and customer complaint management.
laws, regulations, guidelines, policies and work requirements in security, data security and other aspects; review and approve the company’s network security development strategy, medium and long-term plans, and related
Regulations and major decisions; organizing and coordinating major network security management issues among the company's various networks, and coordinating the overall network security work of the company. The company adopts a multi-department joint handling model such as the marketing center and pharmacovigilance department to improve the efficiency of complaint handling through online information circulation. Complaints will be made in accordance with relevant procedures
It is divided into categories I-V according to the severity, and the processing time limit of each link is clearly defined. The quality assurance department will take the lead in organizing relevant personnel to carry out complaint investigation, analyze the root causes, and implement rectification measures.
Improvement measures were taken, and customers were satisfied with the response to the survey letter. In addition, the company summarizes product complaints every quarter and holds company-level analysis meetings to promote product quality and customer system construction.
Satisfaction continues to improve.
The company has formulated relevant systems such as the "Information Security Management System", "Information Security Confidentiality Measures", "Network and Information Security Incident Emergency Response System", "Computer and Network Application Management System", etc. Among them, through the "Network and Information Security Incident Emergency Response System", network security incidents are graded, the responsibilities and division of labor of each unit are clarified, and early warning response, emergency response, investigation and evaluation, prevention and protection work are carried out in an orderly manner. At the same time, through the "Information Security Management System", the entire process from data collection, storage to sharing is standardized and managed to ensure information security and business compliance.
Provide professional and accurate answers to the vaccine product questions consulted. For example, introduce product features, advantages,
Project Management Issues Understanding and Answering Committee Safety Protection
Scope of application, vaccination contraindications, etc.
The company has built a "NSFOCUS Protection System" that integrates vulnerability detection, application firewall (WAF), intrusion prevention (IPS) and other functions, intercepting an average of 200+ external attacks per month. It proactively discovers hidden vulnerabilities through network security equipment every month, analyzes network attack behavior in real time, quickly handles abnormal network behavior threats, and prevents and reduces business interruption, production and operation losses and social impact risks caused by network security incidents; in addition, through
The Provincial Public Security Department organized a practical drill of "Operation Network Protection" to improve emergency response capabilities.
When encountering non-pre-sales product problems, such as after-sales adverse reaction handling, communicate and coordinate with relevant departments in a timely manner to assist relevant departments
Project communication management and committee coordination meeting
Department colleagues responded to questions promptly.
Digital construction
The company has always regarded digital transformation as an important strategic path to achieve sustainable development. By systematically promoting the in-depth integration of intelligent technology and business operations, it continues to improve corporate operational efficiency and decision-making levels. In terms of digital infrastructure construction, it has built an enterprise-level inquiry covering the entire value chain to record basic information such as the name, address, age of the vaccinator, and contact information of the caller, forming a ledger record sheet. Each information system matrix, including CRM, MES, LIMS, DMS and ERP, lays a solid foundation for digital service enterprise operations. information record
project management committee
and retention. At the end of each month, the after-sales issues of this month will be compiled and reported to the Pharmacovigilance Department.
During the reporting period, the company received no complaints involving infringement of customer privacy or loss of customer information, and no major data security or customer privacy leakage incidents occurred.
55 56 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Strong basics
Governance is innovative and efficient
Adhere to the leadership of party building 59 Consolidate the cornerstone of governance 61 Strengthen compliance and risk control 64 Observe business ethics 67 Smooth communication channels 69
SDGs response:
57 58 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
persist
Second, the members of the party branch team take the lead in implementing the spirit of the eight central regulations, actively change their work style, take the lead in going deep into the production line, and lead the research and development of party building. They adhere to the above-mentioned leadership and conduct front-line investigations and research to solve practical problems; party members and cadres set an example in terms of diligence, thrift, integrity and self-discipline, and drive the whole party to play a demonstration and leading role.
It creates a good atmosphere for all employees to be upright and entrepreneurial.
We will implement the spirit of the eight central regulations, promote comprehensive and strict party governance and the deep integration of the company's core business development, and build the style into three
Promote integration and empowerment, and the effectiveness is reflected in practical results such as technological research and development breakthroughs, product quality improvements, and enhanced market competitiveness, and guide party members and cadres to demonstrate the effectiveness of comprehensive and strict party governance.
The company's party branch has always been guided by Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, thoroughly implemented the spirit of the 20th National Congress of the Communist Party of China and the Fourth Plenary Session of the 20th Central Committee of the Communist Party of China, and firmly grasped the core direction of "leading, integrating into governance, and empowering development" to implement the original mission while overcoming difficulties and ensuring the company's high-quality development.
The grassroots battle fortress of "exerting strength" has laid a solid red foundation for the company's high-quality development.
The company currently has 74 party members, achieving full coverage of party members in core business areas, ensuring that the party organization plays the political core and supervisory role in key links such as research and development, production, and quality. branch
Case: "Study, publicize and implement Xi Jinping's thoughts on the rule of law and promote the Constitution to be deeply rooted in the hearts of the people" - The 2025 "Constitution Publicity Week" activity department strictly implemented the "three meetings and one lesson" system. Throughout the year, the branch secretary gave 4 special party classes and carried out 12 theme party day activities, covering policy learning, red education, etc., and held a full-scale
We held 4 party member conferences to organize party members to focus on learning important ideas and the spirit of instructions; at the same time, we organized and carried out cardiopulmonary resuscitation (CPR+AED) of "Everyone learns first aid, first aid is for everyone"
Special training, enriching the form of learning activities, and improving the comprehensive quality of party members.
In order to implement the relevant requirements of the China Securities Regulatory Commission's "Notice on Issuing the "2025 China Securities Regulatory Commission System "Constitution Publicity Week" Work Plan" (China Securities Regulatory Commission Fahan [2025] No. 1879), Baike Biotech actively carried out "learning, publicity and implementation of Xi Jinping's Law"
74 4 12 4
"Government Thoughts and Promote the Constitution's Deepening of People's Hearts" publicity campaign, firmly establish the consciousness of studying, respecting, abiding by, and using the law, and rank every time
We will fulfill our social responsibilities to popularize the law and create a good legal environment in the market.
The company's current party members, annual branch secretaries, give special party courses, carry out themed party day activities, and convene all party members meetings.
The company's party branch organized all party members to thoroughly study and implement Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, firmly grasp the requirements of learning ideas, strengthening party spirit, and emphasizing practice, and taught the theme
Education is deeply integrated with corporate governance and business development. Guided by party building, combining learning with application, and striving for practical results, we will solidly promote the theme education to be in-depth and practical, and effectively transform the learning results.
It is a powerful driving force to promote the company's high-quality development. Case: Bearing in mind the history, keeping the original intention, forging ahead and fulfilling the mission, Baike Biology organized to watch the "93 Military Parade"
In order to remember the history of the Anti-Japanese War, carry forward the great Anti-Japanese War spirit, and cultivate the patriotism of party members
Huai, on September 3, the branch organized all party members to watch the "September 1993 Military Parade".
The company takes the implementation of the eight-point regulations of the Central Committee as the starting point to solidly promote the comprehensive and strict management of the party: relive the prosperous years together, feel the might of the country and the military, and gather the strength to forge ahead. This visit
The viewing activity is not only a vivid patriotism education class, but also a profound
Party spirit tempered. After the viewing, party members exchanged insights and talked about their experiences.
With the Party branch as the core, we carry out special study on the spirit of the eight central regulations on a regular basis, through party class lectures, case warning education, etc.
At the meeting, they unanimously stated that they should draw inspiration from the spiritual power demonstrated by the September 3rd military parade.
One is
Form, guide party members and cadres to deeply understand the long-term and arduous nature of work style construction, and integrate the spirit of the eight provisions into the daily education of party members
Strengthen ideological guidance and motivation, remember history, honor martyrs, cherish peace, and create a future.
Build a solid foundation for work style construction and education and management, integrate the requirements for work style construction with specific work such as company operation and management, project management, etc., and promote party members and cadres to strictly implement
Work style and perform duties conscientiously.
59 60 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Consolidate
The company's board of directors consists of 11 directors, including 4 independent directors and 1 employee representative director. Each board of directors has a term of three years. Directors may be re-elected upon expiration of their term, and independent directors shall not be re-elected for more than six years. Employee representative directors are democratically elected by the company’s employees through employee congresses, workers’ conferences or other forms, and there is no need to submit the governance cornerstones of the shareholders’ meeting.
Review; non-employee representative directors are elected by the shareholders' meeting, and director candidates are nominated by the board of directors or shareholders who individually and collectively hold more than 1% of the company's shares. The investor protection institution established in accordance with the law can publicly request shareholders to entrust it to exercise the right to nominate independent directors on their behalf. The list of director candidates is submitted to the shareholders' meeting for resolution in the form of a proposal. A cumulative voting system is adopted when the shareholders' meeting elects two or more directors.
The company's sixth supervisory board originally had 3 members, including 2 male supervisors and 1 female supervisor. In accordance with the requirements of relevant laws, regulations and normative documents such as the "Company Law of the People's Republic of China", "Transitional Arrangements for the Implementation of Supporting Systems and Rules of the New Company Law", "Guidelines on the Articles of Association of Listed Companies (Revised in 2025)" and other relevant laws, regulations and normative documents, combined with the actual situation of the company, the company Baike Biotechnology attaches great importance to the company's standardized governance work, constantly improves the governance structure, clarifies the division of powers and responsibilities, and improves the management system to ensure that the company's operations are standardized, transparent, efficient, and secure A major adjustment was made to the governance structure, and the shareholders' meeting was submitted for approval to streamline the original "three meetings and one layer" (shareholders' meeting, board of directors, board of supervisors and management) into a "two meetings and one layer" (shareholders' interests and the company's long-term stable development. meeting, board of directors and management) structure. The audit committee will exercise the powers of the board of supervisors stipulated in the "Company Law of the People's Republic of China" to further enhance the level of corporate governance and achieve improved quality and efficiency in governance.
board of directors
In terms of management, there are a total of 5 senior executives of the company, including men. Management
The company's board of directors has four special committees, namely the Strategy and Sustainable Development Committee, the Audit Committee, the Nomination Committee, and the Remuneration and Appraisal Committee. Each committee is composed of
4 people, 1 female; divided by age structure, 50 years old
The composition of the board of directors mainly conducts research on professional matters, provides professional suggestions for the board of directors' decision-making, and enhances the scientificity and professionalism of the board of directors' decision-making.
(Inclusive) 1 person below, 4 people over 50 years old. company high
people
Senior management personnel are appointed or dismissed by the board of directors.
Company executives total
Each term shall not exceed the term of the board of directors that appointed him or her.
Strategy and Responsible for conducting feasibility studies on the company's long-term development strategic plans and major investment and financing plans, major capital operations, and asset management projects, and ensuring that management performs their duties in a standardized manner and has clear rights and responsibilities.
Sustainable Development by Gender The Women’s Committee makes recommendations, formulates ESG strategies based on the company’s actual conditions, identifies ESG-related risks, supervises ESG implementation, and reports work to the board of directors.
4 1
male person person
male female
Responsible for reviewing the company's financial information and disclosure; supervising and evaluating external audit work, and proposing to hire or replace external audit institutions;
audit
Supervise and evaluate the internal audit work; be responsible for the coordination between internal audit and external audit; supervise and evaluate the company's internal controls; exercise the "China
Committee Divided by age structure 50 years old (inclusive) The powers of the Board of Supervisors stipulated in the Company Law of the People's Republic of China; Responsible for laws and regulations, the self-regulatory rules of the Shanghai Stock Exchange, the Company's Articles of Association
and other matters authorized by the Board of Directors. 1 4
Dong
things people people over 50 years old will
Under 50 years old (inclusive) Over 50 years old
Responsible for formulating and conducting assessment standards for directors and senior managers, formulating and reviewing remuneration policies for directors and senior managers
Salary
and plans, and regarding the remuneration of directors and senior managers, formulating or changing equity incentive plans, employee stock ownership plans, and incentive targets
and assessment
The committee is responsible for the authorization of rights, the fulfillment of conditions for exercising rights, directors and senior management personnel in arranging shareholding plans, legal and operational arrangements for the subsidiaries to be spun off.
Make recommendations to the Board of Directors on other matters stipulated in laws and regulations, China Securities Regulatory Commission regulations and the Articles of Association.
Responsible for formulating the selection criteria and procedures for directors and senior managers, and selecting candidates for directors and senior managers and their qualifications
Nominate
selection, review, nomination or appointment or removal of directors, appointment or dismissal of senior managers, laws, administrative regulations, China Securities Regulatory Commission regulations
committee
Make recommendations to the Board of Directors on other matters stipulated in the regulations of the Shanghai Stock Exchange and the Articles of Association.
61 62 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Strengthen
Compliance risk control
Remuneration Management for Directors and Senior Management
The company has established a scientific and standardized remuneration management system for directors and senior managers, strictly follows the principles of unifying responsibilities and rights, and combining incentives and constraints to ensure remuneration policies
Be consistent with the company's development strategy and shareholder interests. Among them, the remuneration plan for directors is drawn up by the remuneration and assessment committee of the board of directors, and is submitted to the shareholders' meeting for approval after being reviewed and approved by the board of directors.
The remuneration plan for senior management personnel shall be formulated by the Remuneration and Appraisal Committee and shall be reviewed and approved by the Board of Directors.
The company continues to improve the salary management system and revised the "Remuneration and Assessment Management Measures for Senior Managers of Changchun Baike Biotechnology Co., Ltd." and implementation details in early 2025.
internal control
It will be implemented in accordance with the management measures in 2025 to ensure that the system is compatible with the company's development stage. The company strictly implements the remuneration decision-making process and regularly reviews the remuneration assessment of senior management personnel.
Baike Biotech strictly abides by the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies" and "Review Results of Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange", improves the internal incentive and restraint mechanism of operators, standardizes salary and performance appraisal management, fully mobilizes the enthusiasm and creativity of senior managers, and strengthens internal management standards.
Self-regulatory Guidelines No. 1 - Standardized Operations", "Basic Standards for Enterprise Internal Control" and other laws and regulations have formulated the "Internal Audit Management System" and "Internal Control Evaluation Management System" to ensure the healthy, sustainable and stable development of the company.
and internal control manual to comprehensively coordinate the company's internal control-related work, ensure the effective operation of the supervision mechanism, standardize corporate governance, organizational structure, social responsibility, capital activities and other aspects of work, and improve the company's overall governance level.
The company has established a complete internal control structure. The board of directors has an audit committee, and the audit committee has an internal control department as the internal control evaluation department, which is responsible for the specific organization and implementation of internal control evaluation work. Among them, the Board of Directors assumes the leadership responsibility for internal control evaluation, and is responsible for formulating internal control defect identification standards, reviewing major defects and rectification plans, reviewing and approving the annual internal control evaluation report, and being responsible for the authenticity of the report; the Audit Committee is responsible for reviewing and supervising the effective implementation of internal control, guiding and supervising the internal control evaluation work, assessing the company's risk status, proposing risk management suggestions, reviewing the annual internal control evaluation report and major defect rectification plans and reporting to the Board of Directors; the Internal Control Department follows the principles of comprehensiveness, importance, and objectivity, formulates inspection and evaluation work plans based on the company's operating needs, and carries out relevant inspection and evaluation work.
Responsible for the leadership of internal control evaluation, responsible for formulating internal control defect identification standards, reviewing major defects and rectifying the board of directors
review and approve the annual internal control evaluation report, and be responsible for the authenticity of the report.
Responsible for reviewing and supervising the effective implementation of internal controls, guiding and supervising internal control evaluation work, assessing the company's risk status, and recommending recommendations to the Audit Committee
Risk management recommendations, review the annual internal control evaluation report and major defect rectification plan and report to the board of directors.
Follow the principles of comprehensiveness, importance, and objectivity, formulate inspection and evaluation work plans based on the company's operating needs, and carry out relevant inspections. The company's internal control department
Check and evaluate work.
63 64 The Company's Internal Control Department independently exercises its powers under the leadership of the Audit Committee, conducts various inspections on the establishment and implementation of internal controls, and the authenticity and completeness of financial information, and urges the Company to adhere to the risk-oriented principle and implement "risk analysis, policy process formulation and implementation
Rectification and implementation of internal control deficiencies. In terms of legal risk prevention and control, the company hires professional legal consultants externally and sets up special legal posts in the internal development planning department to provide guarantees for the whole-process operation mechanism of daily operating activities supervision, due diligence, audit supervision, correction and improvement, risk analysis, policy process formulation and implementation supervision, and to prevent daily legal management risks. Obstacle compliance operations. Compliance inspections are carried out at any time as necessary, and the inspected personnel must actively carry out due diligence, audit and supervision, correction and improvement of cooperation, and must not engage in behaviors such as non-cooperation, offensive and defensive alliances, etc.
Full-process operation mechanism and compliance operation mechanism
The company has built a multi-level network covering the headquarters, subsidiaries and various business departments.
Supervision mechanism. The Internal Control Department hires a third-party audit agency every year to carry out the risk management process. Each management team combines historical experience and prediction of changes in the operating environment to identify company-level and operational-level risks from top to bottom, and resolve risk management-related work and related audit work. A total of three major types of audit projects will be carried out in 2025: statutory Promote risk-focused projects; each operating department undertakes risk-focused projects, identifies internal and external risk factors within the management scope from the bottom up, evaluates the risk management and control situation based on "risk levels" and "effective control audits (including annual internal control evaluations, fund-raising audits, and financial yearliness), proposes contingency measures, and provides timely feedback to the leading operations department on risk response summaries to improve the overall decision-making effectiveness of the organization. Audit reports, etc.), subsidiary audits (financial annual report audits), special audits
Plan. At the same time, the company, in accordance with the "Basic Standards for Enterprise Internal Control",
around the internal environment, risk assessment, control activities, information and communication, internal
Risk management is carried out from two aspects: design effectiveness and implementation effectiveness, including internal supervision and other elements.
Conduct internal control evaluation.
According to the "Internal Control Evaluation Management System" and its own business characteristics, all departments and positions of the company collect relevant information comprehensively, systematically and continuously, and conduct risk assessment through risk identification, risk analysis and risk analysis.
It adopts three steps of risk assessment to accurately identify internal and external risks related to control objectives, and assess risk tolerance based on risk loss size and probability of occurrence.
Compliance management
Based on the risk assessment results, each department and each position weighs the risks and benefits based on the risk tolerance, and comprehensively uses risk
Risk avoidance, risk reduction, risk sharing and risk tolerance and other response strategies, through preventive control and discovery control
The company has formulated the "Baike Bio Internal Control Manual", "Baike Bio Compliance Work Management System" and "Integrity Guarantee Agreement Management System", and built a "three lines of defense" compliance risk prevention system during the reporting period.
Implement authorization approval control, accounting system control, property protection control, strategy execution and budgeting in a combined manner
standard system. As the first line of defense, the business department is the first person responsible for compliance management. It is responsible for daily compliance risk identification and investigation, and establishes relevant compliance regulations based on key compliance areas.
Management functions; the internal control functions of the Development Planning Department and the Internal Control Department serve as the second line of defense, responsible for improving the compliance management system and promoting its implementation; the Internal Control Department takes measures such as internal audit control, operational analysis control, and performance evaluation control to achieve effective risk management. As the third line of defense, the 0 function is responsible for independently supervising the effectiveness of the audit compliance management system, handling violations, and assisting in responding to compliance crises. During the reporting period, the company had no major governance risk events.
Major governance risk events
"Baik Bio Internal Control Manual" "Baik Bio Compliance Work Management System" "Integrity Guarantee Agreement Management System"
"Three lines of defense" compliance risk prevention system
Responsible for daily compliance risk identification and investigation, focusing on key compliance areas.
First Line of Defense Business Department
Establish relevant compliance management functions.
Development Planning Department
The second line of defense and the internal control department are responsible for improving the compliance management system and promoting its implementation.
internal control function
The Internal Control Department is responsible for independently supervising the effectiveness of the audit compliance management system and handling violations.
third line of defense
Internal audit function software to assist in responding to compliance crises.
65 66 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
abide by
Anti-unfair competition business ethics
The company strictly abides by the "Anti-Unfair Competition Law of the People's Republic of China", "Measures for the Registration and Management of Medical Representatives (Trial)", "Anti-Commercial Bribery Compliance Guidelines for Pharmaceutical Enterprises" and other relevant laws, regulations and norms, adheres to the principle of fair competition and standardizes business practices. During the reporting period, the company was not involved in any litigation or major administrative penalties due to unfair competition. In 2025, anti-commercial bribery compliance training will be organized in the entire marketing center to provide training on relevant provisions and precautions of the "Criminal Law of the People's Republic of China", "Anti-Unfair Competition Law of the People's Republic of China" and "Compliance Guidelines for Pharmaceutical Enterprises to Prevent Commercial Bribery Risks" from the perspective of preventing commercial bribery. Anti-commercial bribery and anti-corruption
The company attaches great importance to anti-commercial bribery and anti-corruption work and strictly abides by relevant laws, regulations and internal company systems. The marketing center has specially formulated the "Compliance Management System" and "Integrity Guarantee"
Agreement Management System", which clearly prohibits commercial bribery and builds a strong defense line for compliance operations.
The company strictly implements the "Integrity Construction Management System" and the "Integrity Guarantee Agreement Management System", and the marketing center conducts anti-corruption activities with service providers, company business personnel, and the Centers for Disease Control and Prevention on an annual basis.
The signing of the agreement effectively serves as a warning against the risks of commercial bribery while safeguarding the company's legitimate interests. At the same time, the company strictly follows the promotion service agreement and is legal and
Pay service fees to service providers in compliance with regulations, and eliminate the risk of job embezzlement from the system and process levels.
In order to ensure compliance operations and effectively prevent and control risks, the company has set up a dedicated compliance post in the marketing center to be overall responsible for the center's compliance management work. In 2025, the marketing center will be in all centers
Conduct anti-commercial bribery compliance training within the scope to strengthen employees at all levels’ awareness of the dangers of commercial bribery and effectively serve as a warning and deterrent.
2025
1 1.5 3 71
times hour first name
The company organizes and carries out study on the spirit of the eight central regulations. Training duration. Participate in the training of senior executives. Participate in the training of employees.
Case: Baike Biological Organization carries out spiritual study on the eight central regulations
In March 2025, Baike Biological Organization carried out spiritual study of the eight central regulations.
67 68 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
smooth
Investor Relations Management
communication channels
The company has formulated an "Investor Relations Management System" and strictly follows the principles of compliance, equality, initiative, honesty and trustworthiness. The secretary of the board of directors is the person in charge of investor relations management affairs. He is responsible for planning, arranging and organizing various investor relations management activities on the basis of a comprehensive understanding of the company's operations, operating conditions and development strategies. The company's board of directors office, as the functional department of investor relations management, has a dedicated person to undertake the daily management of investor relations under the leadership of the secretary of the board of directors. He is responsible for maintaining various investor communication channels and collecting and transmitting internal information.
The company expands the breadth and depth of communication with stakeholders and enhances their recognition of the company through shareholders' meetings, performance briefings, investor exchange meetings, reception of visits, hotlines, company website columns, new media platforms and other channels. In 2025, the company held a total of 4 performance briefings (including 1 collective performance briefing). Baike Biotech attaches great importance to investor communication and always puts the protection of the rights and interests of small and medium-sized investors in an important position. By improving the system, broadening channels, and standardizing processes, it has established an efficient and
times), held 7 investor exchange meetings; responded to investor concerns a total of 117 times through the Shanghai Stock Exchange's E interactive platform, with a response rate of 100%. A transparent and smooth investor communication system has been established to effectively protect the legitimate rights and interests of all shareholders. During the reporting period, the company had no bad credit record and no debt default event occurred.
Counted more than 90 times. At the same time, the company strictly regulates information disclosure work, and the evaluation result of information disclosure work in Shanghai Stock Exchange for 2024-2025 is A. Maintain a good credit standing.
4 7 117
Protection of rights and interests of small and medium investors
times times times
A total of performance briefings and investor exchange meetings were held through the Shanghai Stock Exchange E interactive platform.
On the premise of ensuring that the shareholders' meeting is legal and effective, the company has taken a number of measures to provide convenience to small and medium-sized shareholders and protect their rights and interests: Total number of responses to investor concerns
100 90A
Open online voting and implement cumulative voting system % remaining times
Response rate Number of investor calls answered at Shanghai Stock Exchange
The evaluation results of the information disclosure work in 2024-2025 stipulate that the shareholders' meeting must open online voting for small and medium-sized shareholders to exercise their votes. It is clearly stated in the company's articles of association and the "Rules of Procedure of the Shareholders' Meeting" that the shareholders' meeting
Voting rights save costs and provide convenience. When voting on the election of two or more directors, cumulative voting is used
system to provide a system for small and medium-sized shareholders to elect directors who represent their own interests.
and procedural safeguards.
Shareholders Rules of Procedure
The company formulated the "Rules of Procedure for the Shareholders' Meeting" to further clarify the powers of the shareholders' meeting, proposal methods, voting procedures, etc. The company strictly complies with the provisions of the Articles of Association and implements separate voting counting for small and medium-sized shareholders for each shareholding and implements an avoidance mechanism for related shareholders.
The East Conference invites professional law firms to witness the meeting and issue legal opinions to ensure that the convening, holding, deliberation and voting procedures of the meeting are legal and compliant. In 2025, the company held a total of 3 shareholders' meetings and reviewed and approved 10 proposals.
When the shareholders' meeting considers major matters that affect the interests of small and medium-sized investors, when reviewing proposals for related transactions, the mechanism for avoidance of related shareholders shall be strictly implemented.
The votes of small and medium-sized investors will be counted separately, and the separate vote counting system will be publicly disclosed. In 2025, the company will have a total of 2 proposals that require the related shareholders to respond.
3 10
As a result, in 2025, the company adopted a total of 4 proposals for small and medium-sized shareholders to evade alone, and the company's 3 directors and supervisors evaded the relevant proposals respectively.
Secondary item
The sole vote fully protects the rights and interests of small and medium shareholders.
The company held a total of shareholders’ meetings to review and approve resolutions
69 70 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Case: "Establish rational investment concepts and enhance risk prevention awareness" - "World Investor Week 2025" event Case: Northeast Securities successfully held "Serving Investors" to share high quality - I am a shareholder "Entering the Shanghai-listed company Baike Biology Event"
In order to thoroughly implement the spirit of the Third Plenary Session of the 20th Central Committee of the Communist Party of China, the Central Financial Work Conference and the Central Economic Work Conference, on September 11, sponsored by the Shanghai Stock Exchange and jointly organized by Northeast Securities and Baike Biotech, "Serving Investors and Sharing High Quality - I am a Shareholder" entered the listed company. Ke Biotech actively carried out the "2025 World Investor Week" publicity activities to continuously enhance investors' risk prevention awareness. Baike Biology event was successfully held.
A delegation of investor representatives visited the company's vaccine production base for an on-site inspection. During the interactive session with the management teams of listed companies, investors actively asked questions around issues such as performance, financial situation, product differentiation and competitive advantages, and the future industry structure.
This event achieved a "two-way journey" between listed companies and investors, which not only enhanced investors' awareness of shareholders, but also strengthened their value recognition and long-term confidence in the company.
Case: "Protecting Financial Rights and Promoting a Better Life" - 2025 "Financial Education Publicity Week" event
In order to thoroughly implement the spirit of the 20th National Congress of the Communist Party of China and the Second and Third Plenary Sessions of the 20th Central Committee of the Communist Party of China, as well as the Central Economic Work Conference and the Central Committee of the Communist Party of China
The financial work conference deployed to effectively prevent financial risks, carried out the 2025 "Financial Education Publicity Week" activities, and continuously improved
Public financial literacy and risk prevention awareness.
Case: Baike Biotech participated in the investor online collective reception day event
On May 27, 2025, the company participated in the "Promoting High-Quality Development and Boosting Investor Confidence - 2025 Online Collective Reception Day for Investors of Listed Companies in Jilin Region" jointly organized by the Jilin Provincial Securities Association and Shenzhen Panoramic Network Co., Ltd.
Case: Baike Biology participated in the "3 Minutes of Science and Technology·Executive Open Microphone" event
In May 2025, the company’s director and general manager Jiang Chun
Come and participate in the "Technology" of the Shanghai Stock Exchange Roadshow Center
Create a 3-minute executive open mic" activity to "innovate
With the title "Creating the Foundation for Development", we systematically introduced the company
In-progress pipeline and marketing strategy.
71 72 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Indicator index
Chapter title GRI Standards Topics in SSE’s Guidelines Chapter title GRI Standards Topics in SSE’s Guidelines About this report GRI 101: Basic Disclosure: Reporting Principles and Practices - Adhere to GRI 305: Emissions Pollutant emissions,
Pollution Prevention Waste Management GRI 102-1: Organizational Profile GRI 306: Waste
GRI 201: Economic Performance Shared Climate Responsibility GRI 308: Climate Change Addressing Climate Change GRI 102-14: Governance Structure GRI 401: Employment
About Baik Bio - - GRI 415: Product Responsibility GRI 405: Diversity and Equal Opportunities
GRI 202: Market Performance GRI 402: Industrial Relations;
protect
GRI 102-16: Values, Vision and Mission GRI 503: Compensation Employees
Employee rights
GRI 102-47: Awards and Recognition GRI 407: Freedom of Association and Collective Bargaining
GRI 102-18: The role of governance structures; Building Together, GRI 403-2: Occupational Health Services
Let’s go to a better future together
GRI 501-1: Governance Institutions GRI 404: Training and Education
GRI 102-26: Identification of impacts, risks and opportunities; GRI 404-1: Training investment and participation
ESG management stakeholder communication
GRI 308: Climate Change Implementation GRI 403: Occupational Health and Safety Product and Service Safety
Safety production and quality, employees GRI 102-27: Definition of material issues GRI 403-1: Occupational health insurance assessment
GRI 102-31: Stakeholder Engagement; GRI 410: Local Communities
sow
social contribution
Public welfare hope
GRI 104: Stakeholder Engagement GRI 203: Indirect Economic Impacts
GRI 307: Environmental Compliance GRI 102-33: Investment in R&D
Environment GR I304: Biodiversity Adhere to GRI 201-2: Investment in R&D
Environmental compliance management Innovation-driven compliance management Innovative research and development
GRI 301: Material Use GRI 102-34: Intellectual Property
solidify the foundation,
Tough and ingenious,
Anchoring green development goals
GRI 309: Environmental expenditures illuminate the glimmer of health GRI 415-2: Product design and R&D
Lean GRI 302: Energy Energy Utilization, Water Utilization, Compliance with GRI 411: Human Rights Assessment
Resource Utilization GRI 303: Water Resources Circular Economy Science and Technology Ethics GRI 415: Product Responsibility
73 74 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Chapter title GRI Standards SSE "Guidelines" topic Chapter title GRI Standards SSE "Guidelines" topic GRI 413: Supply chain environmental compliance 416: Anti-corruption
Stable and abiding by
supply chain security supply chain security supply security business ethics
GRI 102-43: Supply Chain Management GRI 505: Ethical Conduct and Anti-Corruption
GRI 415: Product Liability GRI 417: Antitrust and Anti-Unfair Competition
GRI 307-1: Environmental Compliance Certification GRI 102-45: Information Disclosure Practices
Improve product and service safety
GRI 414: Consumer Rights GRI 506: Information Disclosure
Tough craftsmanship, strong foundation,
Product quality and quality
Light up the glimmer of health, manage innovation and efficiency
GRI 415-3: Product Complaint Handling GRI 504: Shareholder Rights
smooth
-
communication channels
GRI 415-1: Product Information and Labeling GRI 102-46: Investor Communication
GRI 417: Antitrust GRI 504-1: Exercise of shareholder rights
GRI 102-39: Technology investment GRI 504-2: Protection of small and medium shareholders
GRI 201: Economic Performance Appendix Key Performance Table GRI 102-50: Performance Indicator Disclosure -Guard Data Security
Data security and customer privacy protection
GRI 414-3: Customer Privacy Protection
GRI 102-40: Data Security
GRI 501-2: Governance Bodies Capacity Key Performance Table
GRI 501-1: Composition of the governance body
Environmental category
persist
GRI 505: Ethical Conduct and Anti-Corruption -
Party Building Leading Indicator Unit 2025 GRI 416: Anti-corruption
Total water consumption tons 760,417 strong basic,
Governance innovation and efficiency GRI 505-1: Anti-corruption policy Fresh water usage tons 741,716 Total reused water usage tons 18,701 GRI 501: Governance structure
Consolidate Proportion of reused water consumption % 2.50 GRI 502: Director Accountability -
cornerstone of governance
Total energy consumption tons of standard coal 25,722 GRI 503: Salary
Natural gas consumption tons of standard coal 18,072 GRI 102-28: Internal control system
Purchased electricity tons of standard coal 7,650 GRI 501-3: Internal control Purchased energy consumption tons of standard coal 25,722 Enhanced
- Clean energy consumption tons of standard coal 18,072 Compliance risk control GRI 102-29: Compliance system
Clean energy consumption % 70.26 GRI 307: Environmental Compliance
Wastewater discharge tons 608,820 GRI 102-26: Identification of impacts, risks and opportunities
75 76 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Environmental category Social category
Indicator Unit 2025 Indicator Unit Second type of pollutant discharge in wastewater in 2025 - - Number of newly hired employees Person 108 COD tons 14.46 Number of employees participating in democratic management activities 2 Ammonia nitrogen tons 0.09 Number of employees participating in democratic management activities Person-time 191 Number of wastewater treatment facilities 4 Total number of safety training times 16 Emissions of waste gas pollutants - - Total length of safety training hours 14 NO tons 10.13 Number of participants in safety training Person-time 1,264 X
Disposal volume of hazardous waste (hazardous waste) tons 267.87 Safety training coverage rate % 100 Major environmental incidents received by relevant departments such as the ecological environment during the reporting period Ten thousand yuan 0 Number of safety accidents 0 Amount of administrative penalties
Work injury rate % 0.15 Total investment in environmental protection Ten thousand yuan 108.96
Investment in employee assistance RMB 32,000 Total investment in environmental protection as a proportion of operating income % 0.18
Number of employee training sessions 3,636 Environmental protection tax paid RMB 10,000 2.87
Employee training expenditure RMB 10,000 45.25 Total employee training hours Hours 173,247 Average employee training hours Hours 140 Employee training coverage rate % 100 By gender structure:
social category
Proportion of male employees trained % 59Indicator Unit 2025
Ratio of female employees trained % 41Number of employees 1,252
By employee type:
Breakdown by gender structure:
Percentage of senior management employees trained % 1Number of male employees Person 734
Proportion of middle management training % 8 Number of female employees Person 518
Ratio of grassroots employees trained % 91Number of disabled employees Person 2
Major safety and quality incidents related to products and services that occurred during the reporting period RMB 10,000 0Number of ethnic minority employees Person 91
Amount of damage involved in liability accidents 0 divided by professional composition:
Number of products that must be withdrawn and recalled due to health and safety reasons % 0 Number of production personnel Person 606 Percentage of products that must be withdrawn and recalled due to health and safety reasons
Number of sales staff Person 114 Number of customer complaints Cases 5 Number of technical personnel Person 239 Number of customer complaints resolved Cases 5 Number of financial personnel Person 12 Customer complaint resolution completion rate % 100 Number of administrative staff Person 155 Amount involved in data security incidents Ten thousand yuan 0 Number of R&D personnel Person 126 Number of incidents of leaking customer privacy Cases 0
77 78 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
social category social category
Indicator Unit 2025 Indicator Unit Amount involved in leakage of customer privacy in 2025 RMB 10,000 0 Number of trademark rights Pieces 35 Amount of R&D investment RMB 10,000 24,884.39 Number of trademark rights per million revenue Pieces/million yuan 0.06R&D investment as a proportion of operating income % 41.13 Number of software copyrights Pieces 1Number of R&D personnel People 126 Number of software copyrights per million revenue Pieces/million yuan 0.002 Proportion of R&D personnel % 10.06 Number of suppliers Home 1,398 Divided by gender structure: Number of suppliers in mainland China Home 1,351 Number of male R&D employees People 64 Number of suppliers in Hong Kong, Macao and Taiwan Home 0 Number of female R&D employees People 62 Number of overseas suppliers Home 47 Age structure category: Number of suppliers whose cooperation has been suspended due to non-compliance Home 0 Under 30 years old (excluding 30 years old) People 28 Number of potential suppliers rejected due to non-compliance Home 0 30-40 years old (including 30 years old, excluding 40 years old) People 56 Number of suppliers who have obtained ISO 9000 certification Home 140 40-50 years old (including 40 years old, excluding 50 years old) People 30 Number of suppliers who have obtained ISO 14000 certification Home 100 50-60 years old (including 50 years old, excluding 60 years old) Person 10 Number of suppliers who have obtained ISO 45001 certification Households 100 60 years old and above Person 2 Amount invested in public welfare activities Ten thousand yuan 27.48 Divided by education level: Total number of public welfare activities times 1 Number of doctoral graduate R&D employees Person 16
Number of R&D employees with master's degrees: 54
Number of undergraduate R&D employees: 39
Number of specialized R&D employees: 10
Number of R&D employees with junior college degree or below: 7
Number of patent applications 5
Number of invention patent applications 5
Number of utility model patent applications 0
Number of design patent applications 0
Number of authorized patents 6
Number of invention patents granted 2
Number of utility model patents granted 4 pieces
Number of design patents granted 0 pieces
Number of valid patents 55
Number of valid patents per million revenue pieces/million yuan 0.09
79 80 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Governance category Social category
Indicator Unit 2025 Indicator Unit Unit Number of party branch meetings in 2025 times 12 Number of major lawsuits Cases 0 Number of party branches 1 Number of arbitration matters Cases 0 Number of party members 72 Number of violation penalties 0 Number of board members 11 Total amount of violation penalties RMB 0 Number of men on the board of directors Person 9 Number of roadshows (performance briefings) times 4 Number of women on the board of directors Person 2 Number of investor exchange meetings 7 Number of independent directors Person 4 Number of investors received (Number of institutions) Person times 83 Number of non-independent directors Person 7 Number of platform responses 117 Proportion of outside directors % 72.73 Number of investor calls answered 90 Proportion of independent directors % 36.36 Number of shareholders’ meetings held 3 Number of board of directors meetings 10 Attendance rate of directors at shareholders’ meetings % 100 Number of audit committee meetings 4 Number of regular reports disclosed 4Number of Remuneration Committee meetings 1 Number of temporary announcements issued 45Number of Nomination Committee meetings 2
Number of meetings of the Strategy and Sustainable Development Committee: 3
Number of senior executives: 5
Number of male senior executives Person 4
Number of female senior executives Person 1
Anti-commercial bribery and anti-corruption training hours hours 540
Length of management participation in anti-commercial bribery and anti-corruption training hours 9.5
Number of hours employees participated in anti-commercial bribery and anti-corruption training hours 530
Total number of persons receiving anti-commercial bribery and anti-corruption training 290 persons
Number of directors who received anti-commercial bribery and anti-corruption training Person-time 5
Number of managers who received anti-commercial bribery and anti-corruption training Person-time 7
Number of employees who received anti-commercial bribery and anti-corruption training Person-time 280
Number of corruption prosecution cases 0
Litigation or major actions due to the company’s unfair competition during the reporting period RMB 0,000
The amount of political penalties involved
81 82 2025
Environmental, Social and Corporate Governance Report Changchun Baike Biotechnology Co., Ltd.
Feedback Disclaimer
The information contained in this report does not constitute any investment advice. Investors should not use such information to replace their independent judgment or make decisions solely based on such information. The company also assumes no responsibility for the use of such information. Dear reader, Hello:
We assume no responsibility for any losses caused or that may be caused by the information in this report. The information published by our company is true and accurate. If there is any inconsistency with the statutory disclosure documents, the statutory disclosure documents shall be used.
Document shall prevail. The copyright of the picture belongs to the original author. If there is any infringement, please inform us and delete it. Thank you very much for taking time out of your busy schedule to read "Bikke Biotechnology 2025 Environmental, Social and Corporate Governance Report". We sincerely look forward to your comments and suggestions on the report and our work. You can feedback the completed questionnaire to us by mail or scan and email to provide your valuable opinions. Thanks!
- Which type of stakeholder does your workplace belong to?
Internal management Shareholders/investors Internal employees Suppliers/partners Customers and potential customers
Government and regulatory agencies Community Experts and scholars Non-governmental organizations Public Others (please specify)
- Is the information you are concerned about reflected in the report?
Yes General No
- Your overall evaluation of the 2025 Environmental, Social and Corporate Governance (ESG) Report:
·Readability (the expression is easy to understand, the design is beautiful and engaging, and it is easy to find the required information)
3 points (better) 2 points (average) 1 point (poor)
· Credibility (the reported information is authentic and credible)
3 points (better) 2 points (average) 1 point (poor)
·Information integrity (taking into account both positive and negative aspects of information, and meeting your information needs)
3 points (better) 2 points (average) 1 point (poor)
- Can you easily find the information you are interested in in the report?
Yes General No
- In addition to what has been disclosed in the report, what information would you like to see more?
83 84